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Péptidos activos em membranas são relevantes em diversos campos da biomedicina. Os 
péptidos translocadores de membranas (CPPs), em particular, são promissores na administração de 
fármacos, incluindo em terapia génica.  
O presente trabalho teve por objectivo identificar novas sequências CPPs em proteínas 
estruturais de vírus utilizando técnicas bioinformáticas e validação experimental. 270 proteínas 
virais foram examinadas para reconhecimento de potenciais CPPs, tendo sido identificadas 2400 
sequências putativas. 14 CPPs de vírus foram seleccionados para ensaios in vitro como vectores 
para carga génica, utilizando oligonucleótidos de ssDNA como modelo. A eficiência de entrega foi 
monitorizada por espectroscopia de fluorescência, citometria de fluxo e microscopia confocal. 
Adicionalmente, efectuaram-se ensaios biofísicos para compreender propriedades físico-químicas 
necessárias para entrega celular eficiente dos CPPs. Consequentemente, medidas de potencial de 
membrana com di-8-ANEPPS foram utilizados ao estudar afinidade de CPPs para membranas. Foi 
usado dicroísmo circular para inferir estruturas secundárias induzidas em CPPs por membranas 
lipídicas. A conjugação entre CPPs de vírus e oligonucleótidos foi também avaliada por dispersão 
dinâmica de luz para aferir a formação de complexos entre vectores e carga transportada. 
Seis dos péptidos demonstraram eficiência na entrega de ssDNA a células. Dados biofísicos 
demonstraram que a eficiência da entrega de CPPs está dependente das interacções entre CPPs e 
lípidos, assim como da capacidade de conjugação com a carga a transportar. Dois CPPs foram 
particularmente eficientes e deverão continuar sob desenvolvimento e caracterização. 
Proteínas estruturais de vírus são uma fonte viável de CPPs, e podem ser exploradas para 
outras biotecnologias de péptidos activos em membranas, nomeadamente péptidos antimicrobianos.    
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Membrane-active peptides provide wide therapeutic potential in several biomedical areas. 
Among these, cell-penetrating peptides (CPPs) are highly promising molecules in drug delivery, 
particularly when applied to gene therapy applications. 
This work aimed to identify novel CPP sequences in structural viral proteins using 
bioinformatics, followed by experimental validation. 270 structural viral proteins were screened for 
the existence of potential CPP sequences, which resulted in the identification of 2400 putative 
sequences. A subset of 14 viral CPPs was selected for in vitro testing as gene cargo vectors using a 
15-mer ssDNA oligonucleotide as a model. Delivery efficiency was monitored by fluorescence 
spectroscopy, flow cytometry and confocal microscopy. Furthermore, biophysical assays were 
conducted to understand the physical-chemical properties required for effective CPP cellular 
delivery. As such, membrane dipole potential sensing, using di-8-ANEPPS, was employed to study 
the affinity of CPPs towards lipid membranes. Circular dichroism was used to infer about lipid 
membrane-induced CPP secondary structure. Moreover, conjugation between each viral CPP and 
oligonucleotides was evaluated by dynamic light scattering to infer about the proper formation of 
vector:cargo complexes. 
Six peptides demonstrated clear efficiency in delivering ssDNA into cells. Biophysical data 
showed that the molecular determinants required for an efficient CPP are dependent on CPP-lipid 
interactions and proper conjugation with the cargo to deliver. Thus, two CPPs were particularly 
efficient and should be considered for future development and characterization.  
Structural viral proteins are a viable source for new CPPs, which may also be explored for 
other membrane-active peptide biotechnologies, namely antimicrobial peptides. 
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1. Introduction   
1.1. Drug delivery systems  
The administration of classical drugs, subscribed to Lipinski’s rule of five, as well as of 
state-of-the art therapeutics, such as protein/peptide or gene therapies, are a major aspect of medical 
care. However, these treatments are often associated with undesirable outcomes. For instance, 
adverse off-target effects can result from an inherent lack of specificity of pharmaceutical 
molecules, and are associated with high dosages and toxicity (1). Additional downsides of these 
drugs include systemic degradation and clearance by the renal and reticulo-endothelial systems, 
poor solubility, stability, circulation time, and bioavailability/biodistribution in vivo (2-4). 
Furthermore, macromolecules cannot transpose the cytoplasmic membrane of cells, which is a 
limiting step in the development of biomolecular therapies aimed at intracellular targets (5, 6). This 
is particularly relevant as it has been estimated that only 10% of the known drugable genome can be 
targeted by conventional drugs (7). Altogether, these issues greatly diminish pharmacological 
potential and are major hindrances to the pharmaceutical and biotechnological industries (2). 
In this context, the emergence of improved drug delivery systems (DDSs) is expected to be 
of seminal importance by providing tools to overcome such limitations. Drug delivery can be 
defined as a multidisciplinary field that deals with the construction of DDSs, also known as vectors, 
capable of carrying therapeutics to their sites of action. The action of DDSs should therefore 
improve the pharmacodynamic and pharmacokinetic profiles of therapeutics (2). Modern DDSs are 
descendants from Ehrlich’s concept of a “magic bullet” (1, 8). Ideally these “magic bullets” should 
promote drug efficacy and reduce the emergence of toxic effects, by protecting and retaining drug 
integrity in vivo, and by constraining its release into the site of therapeutic action. Such a system 
must be biocompatible/ biodegradable to be stably carried throughout the body, and be able to reach 
the site of drug release (3). However, any drug or delivery system is subjected to harsh conditions 
and must override imposing frontiers during their journey through the bloodstream and other 
tissues. For instance, epithelia and endothelia must be crossed by transcytosis, and recognition by 
many of the proteins and immune factors circulating in blood must be avoided (4, 6, 9). In addition, 
selectivity and appropriate drug release are very difficult to translate from the research bench into in 
vivo environments and the transposition of the cell membrane is still an imposing obstacle to 
delivery, even for vectors of latest generation (5, 9). DDSs can be classified into two main groups 
(5), namely viral vectors (10), which are employed in the context of gene therapy, and non-viral 
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vectors (11), which can be tailored to transport a wider range of cargoes such as classical drugs and 
macromolecules.  
 
1.1.1. Viral vectors 
 While theoretically feasible, effective gene therapy practices have been quite difficult to 
achieve as nucleotides are very prone to enzyme degradation (DNAses and RNAses). Furthermore 
these molecules cannot penetrate cells due to high abundance of anionic charges (5). In this regard, 
viruses were the first carriers employed for gene therapy because viruses have developed the 
intrinsic ability to protect, carry and deliver nucleic acids through evolution. These vectors may 
belong to several virus families, for example Adenoviridae, Herpesviridae, or Retroviridae, and 
each one possesses certain advantages and drawbacks (10, 12). In general, viral vectors have the 
advantage to transfect cells with efficiency as they naturally bypass cytoplasmic and nuclear 
membranes using cellular internalization pathways. Viral vectors can also be genetically engineered 
to increase selectivity. However, there are two major drawbacks associated with the use of viral 
vectors: I) limited loading capacity which constrains the amount of genetic material that can be 
carried, but more importantly II) the propensity for eliciting immune responses and the risk for 
induction of mutagenesis, which may not only prevent re-administration, but can seriously 
compromise the patient’s health. Indeed, a past clinical trial with an adenoviral vector has resulted 
in the death of a patient, and two cases of the onset of leukemia in patients treated with 
gammaretrovirus were also reported in another trial (5, 10). 
 
1.1.2. Non-viral vectors 
Contrary to viral vectors, non-viral carriers may be devised to transport every type of 
pharmaceutical load, from nucleic acids, to proteins/peptides, and classical drugs (5). These vectors 
are constructed from an immense variety of structures and materials (2). Non-viral vectors can be 
assembled from organic molecules (e.g. liposomes, polymers, carbon nanostructures or peptides), or 
from inorganic colloids synthesized from such materials as iron, gold or cadmium selenide. Virus-
like particles have also been constructed from chemical engineering of the natural scaffold provided 
by viral capsids (13).  
Due to their fabrication at the nanoscale, these DDSs are collectively known as 
nanoparticles (NPs). NP development is usually divided into three generations. The first generation 
was constituted by simple colloids without surface modifications to achieve passive delivery. The 
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second generation includes the first targeted nanocarriers, functionalized with ligands for specific 
biological receptors (e.g. antibodies) in attempts to increase selectivity. The current and third 
generation is comprised by complex NP systems tuned to bypass physiological obstacles, to 
increase active targeting capacity, and to ensure some degree of temporal control of drug release 
through physical and chemical stimuli (2, 11). However, most of this technology must be further 
optimized before reaching the clinical setting, as it still exhibits considerable drawbacks. These 
include long term biocompatibility concerns, poor retention of colloidal stability in vivo, and the 
need for fine tuning of targeting efficiency and drug release capability (1, 9, 11).  
 Intracellular delivery is another aspect of NP systems that must be addressed. In fact, 
entering through the cell membrane, escaping endosomal compartments before enzymatic 
degradation, and distributing the cargo to a particular organelle are still some of the most 
challenging aspects of drug delivery (14).  In this regard, cell uptake leading to internalization and 
intracellular traffic of biomolecules can occur by a diverse set of endocytosis mechanisms, divided 
into pathways which either proceed by non-specific entrapping of molecules on the cell surface, or 
which are mediated by cell-receptors. This receptor-mediated uptake is especially important for 
last-generation DDSs because it may be exploited for selective internalization of NPs into particular 
cell types. Active targeting thus involves coupling targeting moieties to NPs which are specifically 
recognized by particular cell-surface receptors (2). However, NP cell-targeting strategies are still 
quite inefficient (6, 14). Furthermore the uptake of non-viral DDSs is poorly characterized, as their 
internalization depends on diverse properties such as carrier size, charge, concentration or cell type 
(2, 6). Following cell entry by endocytosis, DDSs must escape from the endocytic vesicles. This is 
due to the fact that as endosomes mature, and eventually fuse with lysosomes, a subsequent drop in 
vesicle pH activates catabolic enzymes responsible for the degradation of molecules entrapped in 
the endocytic vesicles. Development of DDS escape strategies has been reported in the literature, 
such as pH-sensitive or fusogenic peptides (15), the construction of fusogenic lipoplexes (6), and 
the use of dynamic polyconjugates or proton-sponge polymers (9). Nonetheless great amounts of 
research must be conducted so these strategies can be properly adjusted to every NP system in order 
to ensure sufficient activity without eliciting cytotoxicity (6, 9, 15).  
After three decades of development, few NP delivery systems are reaching the market, but 
more are currently under preclinical or clinical trials. Nonetheless many limitations still plague the 
majority of DDSs reported in the literature, which must be solved in order to increase the flux of 
novel developments to clinical settings (11). In this context, cell-penetrating peptides (CPPs) are an 
important and diverse category of biomolecules that can transport drugs through biological 
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membranes with high efficiency (16). CPPs have been extensively employed in the construction of 
third-generation NP delivery systems, as they can be chemically coupled to improve the efficiencies 
of uptake or to promote endosomal escape (17-20). In fact, these peptides have considerable 
advantages relative to other DDSs, such as being less prone to elicit immunological phenomena and 
not depending on receptor-mediated endocytosis as a principal pathway for uptake. Furthermore, 
some CPPs have demonstrated the potential to directly translocate cytoplasmic membranes 
independently of endocytosis, which is a rare trait in biological macromolecules (17). CPPs also 
present a vast repertoire of vector possibilities due to an immense variety of conceivable amino acid 
sequences which might be derived from natural or synthetic sources. These peptides can be 
extensively optimized by tailoring their sequences through mutation of selected amino acid residues 
(e.g. amino acid substitutions, shuffling or truncation of sequences). Several mutant variants of each 
CPP can thus be created, further expanding the variety of conceivable designs.  
Figure 1.1 graphically depicts how CPP-based technology is deeply connected to the field 
of drug delivery (19, 20).  
 
 
Figure 1.1 – CPPs in Drug Delivery – Representation of several biomolecular therapies and available DDSs. 
CPPs can be developed as DDSs or coupled to nanoparticle vectors in order to circumvent biological 
membranes. Adapted from (17).   
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In fact, it can be said that CPP history follows a parallel with that of biomedical 
nanotechnology, in a sense that only now, after decades of intense research and characterization by 
academia, have they been able to start realizing their therapeutic potential (20, 21). 
For their relevance as core subjects in this work, the following chapter will address these 
molecular entities in detail, presenting their mechanisms of action, cargo loading strategies, and 
therapeutic successes and pitfalls. 
 
1.2. Cell-penetrating peptides 
Due to their remarkable properties, peptide-based drugs and drug candidates have been 
steadily increasing in the past decade, with more than 100 having reached the market and a few 
having already surpassed the global sales threshold of a 1000 million US$ (22, 23).  
In this context of investment in peptide therapeutics, the acronym “CPP” refers to the most 
accepted nomenclature for the subset of peptides capable of interacting with, inserting into, and 
ultimately transposing lipid membranes independently of a need for chiral recognition by cell-
surface receptors. In general, these molecules display net positive charge and are comprised by 
amino acid sequences between 5 and 30 residues in length, obtained from naturally occurring 
regions in proteins or designed by in silico methods. As a particular subset of leads for the 
development of vectors that can transport cargo molecules to the interior of cells, CPPs are already 
key players in the field of innovative DDSs (19). 
 
1.2.1. History  
CPP history, illustrated in Figure 1.2, had its genesis 25 years ago with the observation by 
Frankel and Pabo (24) that the HIV-1 transcription-transactivating protein (TAT) could enter cells 
and translocate into the nucleus. Three years later, it was demonstrated that the Drosophila 
Antennapedia homeodomain could be internalized by neuronal cells, leading to the discovery, in 
1994, of the first CPP, penetratin (25). Afterwards, in 1997, Lebleu et al. (26) identified a peptide 
(Tat), containing the minimum functional sequence from HIV-1 TAT required for cellular uptake. 
The first proofs-of-concept for in vivo application of CPPs were reported using peptides and 




Figure 1.2 – CPP Timeline – Main events in early CPP research. Adapted from (28). 
 
Langel et al. (29) introduced the “cell-penetrating” nomenclature with their work on 
transportan, the first chimeric peptide carrier. Several other terms have existed to refer to CPPs, 
such as “protein transduction regions” and “membrane translocating peptides”, but those 
terminologies have been abandoned (30). Another cornerstone of CPP development, the strategy of 
using non-covalent binding between the molecular cargo and CPPs, dates back from 1997. It was 
first based on nucleic acid delivery mediated by MPG (a  short  peptide  consisting  of  hydrophilic  
and  hydrophobic regions), and later on the primary amphipathic peptide pep-1 to deliver peptides 
and proteins (16, 31, 32). A final relevant event in CPP history was the demonstration by Wender 
and Futaki et al. (33, 34) that octa-arginine sequences were sufficient for eliciting cellular and in 
vivo peptide uptake, originating R8 and the family of poli-arginines, which are currently among the 
most extensively studied CPPs (30).  
Ever since the discovery of penetratin and Tat, researchers have been steadily increasing the 
pool of known CPPs, originated from natural, synthetic or chimeric sources (28). Some 
representative examples are listed in Table 1.1. Furthermore, the CPPsite webpage 
(http://crdd.osdd.net/raghava/cppsite/) (35) constitutes a major curated database for CPPs 






Table 1.1 – Nomenclature, origin, sequence and cargo type of representative CPPs. Adapted from (36) 
Peptides Origin Sequences Cargo types 

































PPTG1 Chimeric GLFRALLRLLRSLWRLLLRA Plasmid 
Cationic peptides 




LGTYTQDFNKTFPQTAIGVGAP Protein/plasmid DNA 






1.2.2. Biochemical requirements for CPPs 
The exact biochemical properties that confer cell-penetrating activity to a peptide have not 
yet been identified. This is due to a great variety in the amino acid sequences of CPPs and the fact 
that they are divided into families which do not share sequence similarity (30, 37). However, 
general biochemical profiles have been found to correlate with CPP activity, such as particular 
configurations in charge, hydrophobic amino acid residue content, and a propensity for folding into 
secondary structures in membrane environments. 
In terms of the first biochemical property, net positive charge at physiological pH is the 
most recognizable feature of these peptides. Although there are rare exceptions (e.g. the anionic 
peptide SAPE (38)), the vast majority of CPP sequences are enriched in basic amino acid residues, 
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namely arginines and lysines, which are determinant for their activity. For example, Tat is highly 
cationic with 6 arginine and 2 lysine residues, and it was found that substituting any of its basic 
residues by a neutral alanine would markedly reduce uptake, while substitution of uncharged 
residues would have no effect on Tat activity (39).  Furthermore, it has been found that arginines 
potentiate internalization relative to lysines, although often at a cost of an increase in toxicity (39, 
40). Arginine is the most basic of all amino acids, because its side chain ends with a guanidinium 
group which allows multiple hydrogen bonding with anionic and polar molecules. Thus, arginine 
can form bi-dentate hydrogen bonds with phosphates moieties of more than one lipid headgroup. 
On the other hand, lysine can only form monodentate hydrogen bonds with molecules and therefore 
can only interact with a single lipid. As such, arginine rich peptides can bond with more 
zwitterionic and anionic lipids than their lysine rich counterparts (39, 40). The magnitude of charge 
is equally linked to internalization efficiency, and it has been demonstrated that in some peptides a 
minimum of 8 positive charges was required for efficient translocation (33). 
Hydrophobic residues are also regularly present in CPP sequences, and in these cases may 
be critical for internalization. For instance, a study in the CPP pVEC demonstrated that single 
amino acid substitutions in a terminal hydrophobic patch decreased cellular uptake of the peptide 
(41). Moreover, other studies showed that the uptake of penetratin was abolished by substitution of 
tryptophan  residues by a phenylalanine (7) or that the uptake of peptide R7 was enhanced by the 
addition of a C-terminal tryptophan (40).     
The relative importance of secondary structure in membrane insertion is still under debate. 
Structure polymorphism has been observed for peptides such as penetratin, reported to assume α-
helical and β-sheet conformations under different conditions (e.g. different model vesicle 
compositions, salt concentrations, or peptide to lipid ratios (P:L)) (40, 42-44). Conversely, studies 
in Circular Dichroism (45), Nuclear Magnetic Resonance spectroscopy (46) and Molecular 
Dynamics simulations(47) have been concordant in finding that the peptide BP100 remains 
unstructured in aqueous environment, but promptly adopts a α-helical conformation in different 
lipid membranes (48). Other peptides, such as Tat and R9, are proposed to be inherently disordered 
(42). Therefore structural flexibility and polymorphism may be important for amphipathic peptides 
(49), without being obligatory in cationic CPPs (50).   
 Altogether, these general considerations suggest that CPP uptake does not depend on a 
single parameter, but on the conjugation of biochemical conditions that render internalization 





Because of the high degree of heterogeneity in CPPs, conceiving straightforward 
classification methods has proven to be hard. Several approaches can be found in the literature, 
namely classification through origin, cargo-loading strategy or physical-chemical characteristics of 
the sequences. 
In terms of origin, CPPs are classified as protein-derived, when originated from regions of 
protein amino acid sequences; chimeric, when resulting from the conjugation of two previously 
existing amino acid motifs; or synthetic, when constructed de novo (52). 
Relative to linkage to the therapeutic agent, CPP-cargo systems can be divided into the 
classes of covalent bonding and electrostatic affinity (53). In the first case, CPPs are attached to 
their cargo via covalent conjugation through cross-linking chemistry or through fusion of CPP tags 
in cloned proteins. In contrast, electrostatic affinity involves non-covalent formation of complexes 
due to attraction between drugs and CPPs of symmetric charges.       
Concerning the physical-chemical classification criteria, Francesca Milletti (7) has recently 
proposed a comprehensive and systematic summary of so-far described CPPs. A representative set 
of 100 well-characterized CPPs, the majority (83%) of which had  positive net charge, was divided 
into the cationic, amphipathic and hydrophobic categories (7, 17, 52). Amphipathic peptides 
comprised the largest of these classes, accounting for 44% of samples. Conversely, hydrophobic 
sequences were the rarest (15%). According to Milletti, a  CPP  is  considered  of the cationic group 
if  it  contains  a  stretch of  positive  charges  that  is  essential  for  uptake,  and  if  its secondary 
conformation does  not  lead  to  formation  of  an  amphipathic  structure. This class included Tat, 
poli-arginines and nuclear location signal (NLS) peptides. The category of amphipathic CPPs 
includes peptides with opposing hydrophobic and hydrophilic regions, and is subdivided into 
primary (amphipatic through sequence) or secondary (amphipatic through spatial conformation) α-
helical, β-sheet and proline-rich peptides, according to the secondary structure that is thought to 
mediate their uptake. Finally, hydrophobic CPPs include peptides mainly composed by apolar 
amino acid residues, either having very low net charge (less than 20% of sequence) or a 
hydrophobic motif determined to be crucial for uptake.  
 
1.2.4. Mechanisms of cellular internalization  
The mechanisms by which CPPs enter cells are still far from resolved. Biophysical assays  
(43) and computational simulations (54) have shed some light on this issue at the molecular scale, 
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by revealing that these peptides can exert profound effects on lipid surfaces. Therefore, it has been 
proposed that the initial steps of CPP uptake involve electrostatic binding between basic amino acid 
residues and negatively charged proteoglycans or phospholipid moieties on the cell surface (39). 
This is followed by peptide insertion into the aliphatic regions of membrane leaflets. In many CPPs 
this insertion step is thought to be related to the influence of hydrophobic residues, or to 
conformational shifts which lead the peptides to acquire an amphipathic structure (30, 39). 
Proceeding stages of the molecular mechanism of cellular entry of CPPs are equally unclear.  
The first studies conducted to ascertain the biological entryway for Tat, penetratin and R9 
used microscopy observations, and fluorescently activated cell sorting, on cells incubated with 
fluorophore-labeled peptides (40). These studies suggested that CPP in vitro uptake could take place 
despite treatment of cells with endocytosis-blocking drugs. Such findings lead to the conclusion that 
these peptides could directly translocate membranes through an energy-independent, non-endocytic 
process (36, 39). However, in 2003, Richard et al. (55) provided evidence that formaldehyde 
fixation prior to microscopic analysis drastically changed the intracellular distribution of CPPs. This 
finding, along with the fact that flow cytometry cannot distinguish between membrane-bound and 
internalized fluorophores, demanded a reevaluation of the mechanisms that had been previously 
described (7, 54, 56). Furthermore, it is now recognized that peptide-membrane interactions, 
cellular uptake and cytosolic distribution, are influenced by such factors as the concentration of the 
peptides, lipids and salts in the solvent, medium pH, lipid membrane composition or cell type (57, 
58) and that cargo molecules, including fluorescent probes, also substantially impact CPP 
internalization routes (59, 60). Thus each CPP/cargo DDS has its own particular behavior and must 
be studied independently. Despite this drawback in unearthing the biological pathways responsible 
for CPP internalization, the vast number of publications in the literature concerning the biological 
and biophysical characterization of CPPs has resulted in the formulation of general models for the 
mechanisms of uptake. Figure 1.3 illustrates some of these models. Thus, CPP cellular uptake is 
thought to proceed through endocytosis or through direct translocation of cell membranes.  
The left panel of Figure 1.3 comprises several endocytic mechanisms which have been 
implied in CPP internalization. Endocytic mechanisms are natural processes occurring in living 
cells that can be triggered by electrostatic interactions with proteoglycans in the extracellular 
matrix, by direct interaction with the plasma membrane or through specific binding to cell-surface 
receptors (40). The influence of CPP interactions with proteoglycans and the plasma membrane as 




Figure 1.3 - CPP cellular entry routes and models of uptake - CPP internalization can be divided into energy-
dependent and energy-independent pathways. The first type comprises clathrin-dependent, caveolae-mediated 
and caveolae/clathrin independent endocytosis, and macropinocytosis. Direct translocation may proceed by 
the torroidal pore model, the barrel-stave model, the carpet model, or via inverted micelles. Adapted from 
(64).   
 
 On the other hand, receptor recognition of target molecules is dependent on their chirality, 
and both L- and D- stereoisomers of a CPP can be equally internalized under the same testing 
conditions (52), i.e it is clear that receptor-mediated endocytosis does not contribute for CPP 
internalization. As illustrated in Figure 1.3, all of the currently recognized pinocytic routes have 
been implicated in CPP uptake (40). For instance, macropinocytosis involves an actin-driven 
invagination of the plasma membrane which forms large irregular vesicles, and several studies have 
supported its involvement in the uptake of poly-arginines, penetratin and Tat (40). Clathrin-
mediated endocytosis, formed by energy-dependent assembly and pinch-off of clathrin-coated pits 
from the plasma membrane, has also been connected to Tat and penetratin (39). Caveolin-dependent 
endocytosis, on the other hand, is lipid raft-mediated and depends on hydrophobic membrane 
cholesterol-rich microregions, the caveolae, which bud off the membrane to form caveosomes (40). 
In this case, co-localization studies of fluorescently-labeled Tat with cholera toxins, which are 
known to internalize via caveolae-mediated endocytosis, supported the uptake of Tat through this 
entryway. However, contrary results were reported by authors who found that treatment with 
inhibitors for caveolae-mediated uptake was unable to abolish Tat internalization (39). Examples 
like these reflect the often contradictory results that have been obtained from different CPP uptake 
studies. In fact, no single endocytosis pathway could yet be resolved as a predominant contributor 
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for CPP internalization, and it is now though that several different endocytic mechanisms may act in 
concert to promote the uptake of each CPP or CPP/cargo system. 
The rightward panel of Figure 1.3 concerns non-endocytic internalization. Although direct 
translocation had been related to artifacts of cell fixation in early studies of CPP uptake, more 
recent assays on live cells have re-established its involvement in the internalization of some CPPs 
(39). In this regard, direct translocation involves peptide action in transiently destabilizing and 
bypassing cell membranes independently of ATP consumption or endocytosis. Figure 1.3 displays 
four pathways which have been proposed for direct translocation of CPPs, namely the torroidal 
pore, barrel stave and carpet models, as well as the inverted micelle model. According to the barrel-
stave model, translocation happens when a number of peptides form a membrane channel by self-
assembly into a barrel-like ring around an aqueous pore. The toroidal pore model is similar as it 
involves the formation of another type of pore, triggered by peptide induction of high curvature 
folds in the bilayer. On the other hand, the carpet model results from an accumulation of peptide 
molecules electrostatically bound to the membrane surface so that when a P:L threshold is reached, 
the barrier is locally destabilized without the formation of pores (65). Finally, the inverted micelle 
model states that disturbances in lipid bilayers lead to the formation of inverted micelles that trap 
the CPPs in their hydrophilic core until further destabilization, effectively releasing the molecules 
into the cytosol (64, 66). Additional models for peptide transposition mechanisms, e.g. driven by 
membrane potential differences, can also be found in the literature (67).  Nonetheless, it should be 
noted that, although informative, such models are limited approximations, and thus may not fully 
describe the complex molecular interactions that take place during CPP activity (68). 
As a consequence of the former paragraphs, it should be realized that several kinds of 
endocytosis and translocation mechanisms may act in concert to promote the internalization of each 
CPP/cargo system. Indeed, this notion is gaining increasing support and acceptance in CPP-related 
literature (20, 39). 
 
1.2.5. CPP-mediated gene therapy 
CPP delivery strategies have gained considerable popularity in the past decade, and more 
than 1000 applications have already been attempted both in vitro and in vivo (54). In fact, since the 
first in vivo proofs-of-concept, CPPs have been used in therapies to target multiple disorders 
including asthma, ischemia, diabetes, or inflammation (54, 56). Therapies for cancer have also been 
intensively studied, and CPPs are equally investigated for treatment of brain related illnesses 
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because of their ability to cross the blood-brain barrier (69, 70). In this regard, the application of 
CPPs as gene and oligonucleotide therapy vectors is a particularly promising and widely researched 
area (28). 
Gene therapy is a powerful form of treatment by which cells are supplied with exogenous 
genetic material that complement, substitute, or suppress functions linked to disorders (5). Cancers 
(e.g. melanomas, carcinomas, leukaemia), genetic (e.g. cystic dibrosis, X-linked severe combined 
immunodefficiency disorder), auto-immune (e.g. diabetes type 1), neurodegenerative (Parkinson’s 
disease, multiple sclerosis) and cardiovascular disorders and viral infections are just some of the 
highly problematic illnesses that may be overcome by a continued investment in this type of therapy 
(5, 10, 71). Diverse approaches to gene therapy have been developed in the past twenty years (72), 
namely the use of plasmids containing genes of therapeutic interest, or splicing correction and 
silencing of deleterious genes via antisense oligonucleotide technology. These strategies may be 
achieved using single strand DNA (ssDNA), small interfering RNAs (siRNA) or microRNAs, or by 
steric  blocking  DNA  mimics, such as phosphorodiamidate morpholino oligomers (PMO) and 
peptide nucleic acids (PNA) (72-75).  Extensive examples of CPP conjugation to all of these 
molecules for gene delivery, antisense knockdown or mRNA splice correction can be found in the 
literature (36).  
For instance,  CPP -mediated  delivery  of  plasmid  DNA  has been achieved in cultured  
cells,  chiefly  through  non -covalent approaches that have included CPPs such as MPG,  Tat  and  
poly-arginines (36). In vivo results have also been reported. For instance, the intravenous injection 
of a luciferase expression plasmid conjugated with the peptide PPTG led to significant gene 
expression in the mouse lung (76). In another study, a recombinant form of Tat was mixed with a 
therapeutic plasmid encoding α-galactosidase A and injected into muscles of knockout mice models 
for a lysosomal storage disease. In this latter case the skeletal muscle expression of galactosidase 
was significantly enhanced in comparison to injection of DNA alone (58).  
Likewise, CPP strategies have been developed for the administration of siRNA in vitro and 
in vivo. For example, MPG has been reported to enhance siRNA delivery in several cell lines, but 
has also been applied for in vivo delivery of OCT-4 targeting siRNA into mouse blastocysts (77). 
Furthermore, Tat conjugated with an RNA-binding motif was reported to block epidermal growth 
factor  in vivo (78), and the fusion of a small peptide from rabies virus glycoprotein to R9 was used 
to deliver siRNA to the CNS of mice (79).  
Finally, the conjugation of oligonucleotide mimics to CPPs has also been extensively 
assayed in peptides such as transportan Tat, penetratin and oligo-arginines (36). In vivo results have 
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also been reported. Prominent examples include several synthetic and chimeric peptides which have 
been tested in the delivery of therapeutic PMOs to animals models of Duchenne muscular dystrophy 
(80).  
 These are only a few instances of a large amount of proofs-of-concept related to the 
viability of CPP-mediated gene delivery. Although encouraging results have been attained, CPP 
research still has an important role in the translation of these applications from the work bench to 
the clinical setting (21).  
 
1.2.6. Current drawbacks of CPPs 
Despite demonstrating remarkable properties and constituting promising vectors, CPPs 
encounter obstacles to clinical translation. Lack of selectivity, and concerns about toxicity, are 
perhaps obvious, but problems like reduced in vivo efficacy, poor bioavailability, instability, and 
short time-span, must also be considered (7). A number of studies have assessed the toxicity of CPP 
in vitro, while in vivo information from animal assays remains more scarce (58, 81-84). In general 
CPP have demonstrated low levels of cytotoxicity (85, 86). The kinetics and biodistribution of some 
CPPs have also been studied in vivo establishing that these therapeutics can potentially be safe and 
target most tissues in the body (64, 87-89). However, downsides such as rapid blood clearance and 
preferable distribution to the liver, kidneys, spleen, bowels and lungs, have also been reported (90, 
91). In this regard, phagocytosis by the reticuloendothelial system, proteolysis by intestinal 
enzymes, as well as interactions with blood components can severely decrease the circulation of 
CPPs.  
However several strategies are being investigated to counter CPP drawbacks, such as 
substitution of biological L- amino acids for protease resistant R- stereoisomers, chemical 
optimization  of  structure,  or  covalent linkage  to shielding  molecules, such as poly-ethylene 
glycol (21, 64). Clearly CPPs have demonstrated great therapeutic potential but there is still the 
need and ample opportunities to expand the known pool of peptide leads and to continue studying 
the biochemical properties which are determinant for their activity. 
 
1.3. Structural viral proteins and CPPs 
It was previously mentioned that the discovery of TAT protein’s natural translocation 
ability is often held at the beginning of CPP research. Additionally the Tat peptide was one of the 
first CPPs to be discovered and one of the most extensively studied peptide DDSs (40). However, 
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more examples exist of CPPs derived from viruses, concretely from structural components of viral 
shells. Vp22 is one such example, found in a Herpes Simplex virus tegument protein capable of 
translocating membranes (92). Additional CPPs have been originated from the glycoprotein H of 
the same virus (93), or from the k8 protein of Herpesvirus 8 (94). Other sources of CPPs from 
structural viral proteins have included the classical swine fever virus’ envelope protein (95), the 
human respiratory syncytial virus surface glycoprotein G (94), the hepatitis-B surface glycoprotein 
(96) and a N-terminal domain of its X protein (97), or the capsid units of the flock house virus (98), 
the brome mosaic virus (99), and the alphavirus (94). Furthermore the extensively studied chimeric 
CPPs pep-1 and MPG comprise a NLS from the Large T antigen from simian virus 40 (16), and the 
hydrophobic motif of MPG is derived from the fusion sequence of the HIV protein gp41. 
Nonetheless, despite these well-established precedents, the percentage of CPPs derived from viruses 
is still very limited when compared to the total number of currently known CPP sequences, as 
indicated in Figure 1.4. This suggests that structural viral proteins are an underexplored source of 
therapeutic peptides.   
 
 
Figure 1.4 - Sources of CPP Sequences – Each percentage was calculated based on the amount of hits on 
CPPsite (35). 
 
In fact, viruses are fascinating, complex and very diverse molecular entities that have 
evolved, through aeons of selective pressure, a wide array of strategies to protect and deliver 
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genomes to their replication sites in the interior of obligatory cellular hosts (100). Moreover, viruses 
persist throughout all of life’s regions and exhibit a large number of taxa with differing sizes and 
morphologies. Simple viruses can possess a single genome molecule contained within a protective 
structure, the capsid or nucleocapsid. These structures may be organized in a variety of 
arrangements, such as helical or icosahedral patterns (101). More complex virions have additional 
elements, including non-structural proteins with diverse roles in the viral cycle (102) (e.g. genome 
replication, modulation of host gene expression), and the envelope (103), a lipid bilayer surrounding 
the viral core in association with a protein shell. A distinction between enveloped and naked viruses 
is important because the strategies to transpose cell barriers employed by species within each group 
may be quite distinct (104), as illustrated in Figure 1.5.  
 
 
Figure 1.5 - Diversity in viral cellular entry mechanisms – Structural proteins from capsid, envelope or 
membrane elements mediate the uptake of virions into host cells through a variety of strategies. Adapted from 




As the figure indicates, some viruses gain access to the cytosol through the cytoplasmic 
membrane (106), while others are first internalized and transported through endocytic vesicles 
(107). In addition, viruses have also been shown to exploit the proximity between neighboring cells, 
spreading from the interior of a host directly through the membrane to the cytosol of contacting 
targets (100, 107). Therefore, a fundamental consequence of viral uptake is that virions must 
interact with lipid bilayers to reach their replication sites. In this regard, several mechanisms have 
already been characterized, including the induction of membrane lysis or of fusion events, and the 
formation of pore structures through which genomes can escape (108).  
Due to the propensity that structural proteins from viruses display towards lipid 
membranes, some authors have recognized the similarities between selected regions of these 
proteins and a broad group of peptides, collectively known as membrane-active peptides (MAPs) 
(109-111). These peptides share the intrinsic property of exerting biological effects (antimicrobial 
(45), antiviral (112), anticancer (113)) based on molecular interactions with lipid membranes. 
Indeed, CPPs can equally be classified as MAPs because their activity is related to an affinity for 
lipid structures (109, 114). Given this fact, and the data presented in Figure 1.4, it is surprising that 
viruses have not been more intensively studied in the field of CPPs, and in a wider perspective, of 
therapeutic MAPs.  
Professor Castanho’s lab has combined the subjects of structural proteins from viruses and 
MAPs in the determination of Flavivirus entrance mechanisms through the study of the dengue 
virus (DENV) capsid protein. DENV, an enveloped virus, has three structural proteins termed as 
envelope, membrane, and capsid, relating to the structures from which they are originated. There is 
ample evidence that this virus enters cells through endocytosis and that endossomal acidification 
triggers a fusion type II mechanism (115). This entry strategy consists in the formation of envelope 
protein trimers and their insertion into the host membrane, but  consecutive stages of the process are 
still left up to speculation (116). Recently, Freire et al., from Professor Castanho’s group, have 
found that the C protein is implicated in Flavivirus fusion by demonstration of its inherent capacity 
to permeate cells. For this end, peptides were first derived from the two putative functional domains 
of the C protein monomer, the RNA binding domain – pepR, and the membrane binding domain- 
pepM. Both peptides were found to form stable electrostatic aggregates with ssDNA and to strongly 
favor partition into model membranes, even when conjugated with nucleic acids (111, 117). 
Furthermore pepR and pepM were confirmed as full-fledged CPPs capable of penetrating cells and 
delivering ssDNA with high efficiency (118). Uptake studies suggested that pepR internalization is 
dependent on an endocytic pathway, and that pepM can directly translocate cell membranes in 
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accordance with the inverted micelle model (118). PepR had also previously been reported as an 
antimicrobial peptide (AMP) capable of severely disrupting the outer surface of Escherichia coli 
(119). Furthermore, the full-length DENV C protein was also studied and shown to directly 
translocate cells while delivering nucleic acids in vitro with high efficiency (120). This work also 
proposed a relation between the capsid of Flavivirus and a recent concept of super charged proteins 
(SCP). Liu et al. have found that engineering natural proteins like green fluorescent protein (GFP) 
to express a very high density of positive charges per molecular weight (e.g. GFP wt: -8 to SCP 
GFP: +36 charges) can impart them with the ability to deliver functional cargo to cells, 
outperforming even cationic CPPs (121-124). The authors also found SCPs expressed in the human 
genome, and tested them as DDSs in vitro, effectively establishing that SCPs can occur 
spontaneously in nature (125). Freire et al. have further expanded this idea by identifying the 
DENV C monomer as a SCP. In fact, DENV C protein has a charge to weight ratio of +1.97 
kDa/MW (120) and this value greatly surpasses the cutoff for a protein to be considered super 
charged, set by Liu et al. (of > +0.75 kDa/MW)(125). Freire et al. also studied the prevalence of 
natural SPCs in structural proteins from additional viral families (120) (categorized as elements 
from envelope, membrane or capsid). They found that the great majority of SCPs in the structural 
viral proteome corresponded to capsid elements, including capsids from all other members of the 
Flavivirus family. Additionally it was found that, excluding Tat, all virus-derived CPPs did not 
belong to a natural SCP (120).  
 
1.4. Motivation 
The work described in this document further explores the findings of Freire et al, that viral 
proteins and/or derived peptides are efficient intracellular carriers of genetic cargo. Thus, the main 
objective was to identify specific peptide sequences in structural proteins from viruses with the 
inherent property of interacting with lipid bilayers, and exploit them as delivery vectors for gene 
therapy. To do so, the project assumed a tripartite configuration, as described in the following 
paragraphs. 
The first stage of the work concerned the identification of putative CPP regions (viralCPPs) 
in capsid, envelope or membrane proteins of viral proteomes. This was achieved by collecting a 
large sample of structural viral protein sequences from online databases. These were then uploaded 
to the CellPPD website (126), containing an algorithm for prediction of CPP regions in protein 
sequences. This process resulted in thousands of putative CPP sequences, or viralCPPs. These 
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sequences were grouped together based on pairwise similarity using the software package CLANS 
(127). A total of 150 viralCPPs were selected from the several clusters produced by CLANS. A 
final set of 14 viralCPPs was then chosen from the previous group, to be assayed in vitro and 
validated as CPPs.  
As such, the second stage of the project involved the execution of a protocol for in vitro 
assessment of the 14 viralCPPs to evaluate their capacity in the delivery of ssDNA oligonucleotides 
into cells. Consequently, the peptides were tested as possible DDSs for gene therapy applications. 
This protocol consisted on mixing each viralCPP with Alexa-488 labeled ssDNA oligonucleotides 
to create electrostatically bound complexes, adding them to cells, and incubating the system for one 
hour. After washing, to remove non-internalized molecules, the fluorescence intensity of probe 
retained by cells was evaluated by fluorescence spectroscopy and flow cytometry. Therefore, this 
protocol allowed that the efficiency of viralCPP-mediated ssDNA delivery be evaluated. Confocal 
microscopy was employed to visualize viralCPP delivery of oligonucleotide probes. The effect of 
trypsin on viralCPP activity was also studied, and cytotoxicity assays were conducted to establish 
the influence of viralCPPs on cell viability. 
 Finally, in the third stage of the work, biophysical methodologies were conducted to assay 
biochemical properties of these peptides that could be related to their biological activity. Di-8-
ANEPPS membrane dipole potential sensing experiments were made to assay the degree of 
interaction between each viralCPP and lipid model vesicles. This study was important because 
membrane affinity is linked to CPP activity. Furthermore, circular dichroism spectroscopy was 
employed to detect conformational shifts in viralCPPs in the presence or absence of lipids, a 
common biochemical trait in CPPs. A last set of experiments used dynamic light scattering 
spectroscopy to calculate the hydrodynamic diameter of viralCPP/ssDNA electrostatic complexes. 
Hydrodynamic diameters relay the apparent size of peptide/cargo conjugates which can be linked to 
the efficiency of delivery.   
This work is of relevance in several areas of biomedical research. Indeed, new CPP leads 
could be identified and isolated from structural viral proteins, a previously underexplored source. In 
this regard, the project marked a “return to origins” in the context of CPP research due to the fact 
that its cornerstone - HIV’s TAT– was a viral protein. Furthermore, proof-of-concept was provided 






2. Technical overview 
Experimental procedures conducted in this work concerned: I) the use computational tools to 
identify novel CPP sequences, II) an in cellulo approach to study CPPs combining flow cytometry 
(FC) and fluorescence spectroscopy (FS), III) biophysical studies to assay interactions between 
CPPs and lipid membranes or oligonucleotides. This section provides a brief theoretical background 
for the techniques that were employed during the project.  
 
2.1. Computational tools  
2.1.1. Expasy ViralZone 
ViralZone (http://viralzone.expasy.org/) (105) is a web resource which provides fact sheets 
on all known virus families, combining textbook knowledge with genomic and proteomic 
sequences. For each genus within these families, reference strains have well documented and 
annotated functional and structural data.  
In this work, ViralZone was employed to easily locate a wide range of structural viral 
proteins with clear functional and structural annotated information. Using the Baltimore 
classification system as a starting point, viruses from all known families were accessed. For each 
virus the amino acid sequences corresponding to its structural proteins were collected from the 
UniProtKB (128). These structural proteins included elements from capsid, envelope or membrane, 
according to individual virion morphologies. 
 
2.1.2. CellPPD 
Understanding if a peptide can act as a CPP based on its amino-acid sequence is a non-
trivial problem. This is due to a lack of clear homology in the hundreds of very diverse sequences 
recognized as CPPs, despite the fact that several biophysical studies have revealed biochemical 
features which are common to the majority of CPPs (129). These include properties such as positive 
net charge, relative degree of hydrophobicity and short length, which can be used as general rules of 
thumb for predicting CPP potential (130). Recently, important developments have been made in the 
field of CPP prediction. The onset of CPPsite (35), a database for CPP sequences, as well as a 
growing number of CPPs reported in the literature, has allowed the refinement of prediction 
algorithms. As a consequence, there are now two online tools for predicting CPP potential in amino 
acid sequences, CPPpred (131) and CellPPD (126).        
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CellPPD (http://crdd.osdd.net/raghava/cellppd/) (126) has been used in this work to identify 
putative CPP regions in structural proteins from viruses. The algorithm implemented in CellPPD 
divides proteins into sequences of a length defined by the user (e.g. sequences of 20 amino acids) 
and each sequence is analysed for its CPP propensity. Therefore, the algorithm predicts and relays 
the likelihood that each of those sequences is a CPP. This prediction is conducted by a machine 
learning algorithm instructed by a main dataset of 700 peptides. The algorithm accounts for factors 
such as total amino acid constitution, and relative position of particular amino acid residues in the 
sequence. The evaluation conducted by the CellPPD algorithm also attributes an estimator of CPP 
likelihood, the Support Vector Machine (SVM) score, to each sequence. Per standard definitions, 
protein sequences scoring positive SVM score values are considered CPP regions, and can be 
isolated as potential novel CPP sequences. Additionally, higher SVM scores are related to increased 
CPP likelihood while protein sequences with negative SVM score are considered non-CPPs. This 
algorithm has a probabilistic nature, and the authors report that it can predict CPPs with over 80% 
accuracy. Therefore, each positive prediction by CellPPD must be subjected to experimental 
validation to ascertain that it is a true positive hit, i.e. validate CPP activity. 
 
2.2. Flow cytometry 
FC is a technology that measures several physical characteristics of populations of living 
cells by means of spectroscopic data (132). To fulfill this function, a standard FC apparatus is 
equipped with a fluidics system able to transport single cells through the optical path of excitation 
lasers. The signals generated by the optical system are then individually recorded by a set of 
detectors and digitally processed. Data from FC allows the quantification of particle size and 
relative granularity/internal complexity through light scattering (as represented in Figure 2.1). 
Forward scattered light, scattered off the axis of an incident beam, is proportional to cell size. Side-
scattering, which is refracted or reflected light, can be related to granularity and cellular complexity. 
The correlation between forward and side scattering allows the identification of different  
populations in a heterogeneous pool of cells (133). Fluorescence intensity can also be recorded by 
FC when cells or biomolecules are labeled with a fluorescent probe. In this case, different 
populations can be recognized based on fluorescent staining. 
Data from a FC assays can assume different graphical representations, but histograms and 
2D-scatter plots are the most frequent. In scatter-plots the concept of gating is especially important 
because thresholds can be defined to establish cell populations. Thus, a gate is a graphical/numeric 
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boundary that defines the range of values in which each population is included, so that positive and 
negative events may be distinguished and analyzed.  
In the context of this work, FC was used to quantify the effect of CPPs on the delivery of 
ssDNA labeled with a fluorescent probe Alexa-Fluor 488 (A488). This technique was also 
employed to conduct toxicity evaluations through a Live/Dead assay (134).    
 
Figure 2.1 - Schematics of basic components of a flow cytometer – Samples are loaded and carried by a 
sheath fluid. Hydrodynamic focusing produces a single file in which particles are individually probed by a 
system of lasers. Fluorescence intensity and forward/side scattering of light can thus be recorded and 
transduced to the electronic component of the device. Adapted from (132). 
 
2.3. Biophysical methodologies 
Biophysics is an interdisciplinary field concerning the study of living systems by employing 
theories and techniques from physics. Thus it provides a quantitative analytical approach to many 
biological questions. In this context, an assortment of spectroscopic methods can be used to inquire 
relationships between the physical properties of molecules, such as structure, dynamics and 
function, in order to determine their role in cells, tissues and organs. 
 
2.3.1. Steady-state fluorescence spectroscopy 
Fluorescence results from the absorption of light by a molecule, its excitation, and the 
subsequent emission of light of higher wavelength after loss of energy by nonradiative processes 
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(135) and can be used to assay biological systems by fluorescence intensity, spectrum, lifetime or 
polarization measurements. It is ubiquitous in life sciences research (135, 136) and has made 
important contributions in the study of macromolecules. FS has been particularly seminal in the 
field of membrane-active peptides (137), for it allows to quantify interactions between peptides and 
lipids, for example through the determination of partition coefficients (43). The applications of 
these techniques can be divided into those which depend on the intrinsic fluorescence of aromatic 
amino acids residues (phenylalanine, tyrosine and tryptophan), and those which depend on the 
extrinsic fluorescence of molecular probes.  
In this work, extrinsic fluorescence methodologies were used. In an initial set of 
experiments, ssDNA molecules were labeled with A488 and FC was used to collect its fluorescence 
intensity (A-488 spectrum is shown in Figure 2.2) and relay the efficiency of CPP-mediated ssDNA 
delivery in vitro. FS was also used in membrane dipole potential sensing experiments, described in 
the following paragraphs. 
 
Figure 2.2- Alexa-Fluor 488 Absorption and emission Spectra 
 
Membrane dipole potential sensing 
Another application of FS in this work consisted in using the membrane dipole sensitive 
fluorescent probe di-8-ANEPPS to assay the effect of CPPs on lipid membrane models.  
The electrical potential profile across the cytoplasmic phospholipid bilayer is comprised by 
the transmembrane potential (∆), the surface potential (s) and the dipole potential (d) (Figure 
2.3). The membrane dipole potential, in particular, is generated on the threshold region between 
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aqueous environments and lipid hydrocarbon non-polar chains. It results from the alignment of 
dipoles in water molecules hydrating the outer surfaces of biological bilayers with dipolar residues 
in the lipids (138, 139).  
Macromolecules capable of exerting an effect on lipid bilayers can directly interfere with 
membrane organization or contribute with their own dipoles to the electrical potential of the 
membrane. These molecular interactions result in the alteration of the membrane dipole potential. 
Therefore, dipole potential sensing can be exploited to report interactions between macromolecules 
and lipid bilayers. Fast-response voltage-sensitive fluorescent dyes are typically used in dipole 
potential sensing assays. Among these dyes is the styrylpyridinium probe di-8-ANEPPS (4-[2-[6-
(dioctylamino)-2-naphthalenyl]ethenyl]-1-(3- sulfopropyl)- pyridinium). Di-8-ANEPPS possesses a 
dipole-sensing chromophore, as well as two aliphatic chains that facilitate integration into 
biological membranes, as illustrated in Figure 2.3 (140).  
 
 
Figure 2.3 – Electrical potential across the cytoplasmic membrane (Left panel) Schematics of a di-8-ANEPPS 
molecule in membrane environment (Right panel). Adapted from (138). 
 
Di-8-ANEPPS excitation spectrum shifts in response to changes in dipole potential (141). 
As illustrated in Figure 2.4, red shifts in the excitation spectra (to higher wavelengths) indicate 
drops in dipole potential, while blue shifts (to lower wavelengths) signify a gain. Differential 
spectra are created to report these shifts, and the underlying interactions. This is accomplished by 
subtraction of the excitation spectrum of di-8-ANEPPS in labeled membranes to the spectrum in 
membranes in the presence of interacting molecules. Both spectra are area-normalized prior to 
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subtraction to reflect only spectral shifts. The amplitude of the differential spectrum is correlated 
with the magnitude of dipole potential variations, and therefore to the extent of membrane 
interactions. Furthermore, the fluorescence intensity ratio (R) of both peaks in the differential 
spectrum can be used to quantify the magnitude of interaction (137). This procedure, schematized in 
Figure 2.4, is called a dual wavelength ratiometric assay.  
 
 
Figure 2.4 – Voltage-sensitive probe dual wavelength ratiometric measurements - Differential intensity 
spectra are created by subtracting the excitation spectrum of di-8-ANEPPS in model vesicles (dashed line) to 
the one resulting upon interaction (continuous line). Typical sinusoidal curves are obtained, indicative of 
either a blue or red shift. The ratio (R) of fluorescence intensities corresponding to maximum and minimum 
wavelengths (a/b) in spectra are used to quantify magnitude of interaction. Adapted from (137). 
 
2.2.2. Circular dichroism spectroscopy 
Circular Dichroism (CD) is used to determine protein and peptide structures in solution. A 
CD signal is originated from chiral chromophores which exist in many biomolecules. Optical 
activity is associated to the asymmetric environment that is generated in proteins and peptides by 
the adoption of a secondary structure (142).  
CD spectropolarimeters measure the difference in absorbance of the left (L)- and right (R)- 
components of circularly polarized light (∆A = AL-AR). ∆A is used to estimate ellipticity θ, related 
to the angle between axes that describe the polarization state of light after its interaction with 
optically active moieties (elliptical polarization, Figure 2.5). In peptides and proteins, the peptide 
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and disulfide bonds and aromatic amino acids side-chains act as chromophores. Therefore, by 
collecting a CD spectrum in the far UV region (240–190 nm), peptide bond absorption is used to 
assess the formation of common structural motifs (e.g. α-helices and β-sheets) because they assume 
characteristic spectra, represented in Figure 2.5 (136, 142, 143). CD results are often reported as 
mean residue ellipticity,[ ]  
  
      
 , calculated from mean residue molecular weight (Mr), 
peptide concentration (C) and optical path of light (d).   
CD was thus used in this work as a way to assess peptide secondary structure upon 
membrane binding.  
 
Figure 2.5 – Elliptical polarization of light (Left panel) Differential absorption of left and right components 
of circularly-polarized light results in elliptical polarization of the beam. Idealized CD spectra of protein 
secondary structures (Right panel) α-helices display large CD bands with negative ellipticity at 222 and 208 
nm, and positive ellipticity at 193 nm, β-sheets exhibit a broad negative band near 218 nm and a large positive 
band near 195 nm, while disordered extended chains have a weak broad positive CD band near 217 nm and a 
large negative band near 200nm. Adapted from (142). 
 
2.2.3. Dynamic light scattering 
 Dynamic light scattering (DLS) measures microsecond fluctuations in the intensity of light 
that is scattered while transversing an optical path through a solution of biomolecules. These 
fluctuations are generated by random collision of particles (Brownian motion) which is influenced 
by their size, medium viscosity and temperature. DLS instruments calculate an autocorrelation 
analysis function from these fluctuations of scattered light. This function registers the correlation in 
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the intensities of scattered light detected in-between increasingly longer intervals (delay times) and 
relates it through an exponential decay curve. The averaged diffusion coefficient (D) is relayed by 
the decay rate of this curve. The Hydrodynamic radius (Hr) of the scatterers in solution can then be 
determined by the Stokes-Einstein equation,   
  
     
, where   stands for Boltzmann’s constant, 
  the absolute temperature and   the medium viscosity (136, 144).  It should be noted that the Hr is 
the radius of a hypothetical hard sphere that diffuses with the same speed as the particle under 
examination. However, macromolecules in solution are non-spherical, highly dynamic structures. 
As such, Hr is indicative of the apparent size of the particles in solution. 
DLS was used to probe the formation and quantify the apparent dimension of peptide or 
peptide/DNA molecular complexes in solution.      
 
2.4. Model membranes 
Cellular membranes are highly dynamic and very heterogeneous systems composed of 
several kinds of lipids and proteins. In fact, the fluid mosaic model had to be continuously 
readapted to fit the most recent findings in membrane composition and organization (145). For 
instance, it is now recognized that each organelle has particular lipid content, and that lipid-lipid 
and lipid-protein associations occur by the formation of specialized regions. Membrane asymmetry 
is also functionally important. For example, in most eukaryotic cells the exoplasmic leaflet of the 
plasma membrane is essentially comprised of phosphatidylcholine (PC), the most predominant 
phospholipid in mammalian membranes, and some sphingolipids, whereas the cytoplasmic leaflet is 
enriched in phosphatidylethanolamine (PE) and phosphatidylserine (PS) (146, 147).  
Due to the great complexity of biological membranes, simple artificial membrane models 
have been used in the study of biophysical phenomena. Different classes of biomimetic membranes 
have been developed but lipid vesicles, also known as liposomes, are among the most commonly 
used. Unillamelar vesicles are well-defined, mono-disperse colloids comprised of a single lipid 
bilayer folded into a closed spherical structure (146-149). These vesicles can be obtained with 
different diameters, ranging from 50 nm (small unilamellar vesicles – SUVs), 100 nm (Large 
unilamellar vesicles – LUV) to giant unilamellar vesicles of 400- >1000 nm diameter. 
These models have limitations such as the lack of an extracellular matrix or proteins, and 
incapacity to emulate energy-dependent processes (e.g. endocytosis). However, they have low cost, 
are readily prepared, and most importantly can be assembled from a great variety of commercially 
available lipid combinations, and thus can be tailored to approach any given type of membrane/lipid 
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domain (147, 148). As such they are extensively employed in biophysical assays of peptide-lipid 
interactions, which are highly relevant in MAP research. The lipids 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine (POPC) and and 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-
serine (POPS) were employed in preparations throughout the work described in this document. Due 
to its abundance in eukaryotic cells, POPC is employed in biophysical assays as a standard for 
emulating mammalian membranes (118). However POPC is a zwitterionic lipid, and therefore 
anionic POPS, also present in mammalian cells, was introduced in POPC/POPS (4:1) vesicles to 



























3. Materials and methods 
3.1. Computational method for identifying CPPs in structural viral proteins  
 The primary objective of this work was to identify regions displaying CPP potential in 
structural proteins from viruses. To search for these CPP regions, viral structural proteins had to be 
identified, their amino acid sequences had to be obtained, and putative CPP sequences had to be 
located inside those sequences. To achieve these goals an assortment of in silico tools were used, 
including the ViralZone(105) and CellPPD(126) websites and the CLANs software package (127).  
Using the Expasy Viralzone website, a large sample of annotated structural proteins from 
viruses was located. The amino acid sequences of each protein was collected from the UniProtKB 
database (128). These 270 amino acid sequences from structural proteins of viruses (capsid, 
envelope and membrane proteins) belonging to every branch of the Baltimore system were 
uploaded and scanned in the CellPPD server (126). Putative CPP sequences of 20 amino acids in 
length were screened. All sequences produced by CellPPD for each viral protein were ordered 
according to their SVM score, and all those predicted as non-CPPs (SVM score < 0) were excluded. 
Amino acid sequences scoring positive SVM values were collected and renamed as viralCPPs. 
About 2400 CPP candidates were retrieved from this process.  
To select a manageable set of viralCPPs for experimental validation and exclude iterative 
CPP sequences, the 2400 viralCPP sequences were submitted to CLANS (127), a software package 
for visualizing protein clusters based on pairwise sequence similarity. CLANS produced 35 clusters 
of similar viralCPP sequences which were ranked according to their assigned CellPPD SVM score. 
The top scoring 5% were selected from each cluster, reducing the original set of 2400 viralCPPs to 
150 sequences. From this group, a final collection of 14 viralCPPs (Table 3.1 and Annex A) was 
manually selected for synthesis and experimental testing. The criteria for this manual selection 
consisted in obtaining sequences with distinct biochemical properties and covering a wide range of 
SVM scores (0.06-1.63). Each of the 14 viralCPP sequences were blasted against currently 
annotated  CPP sequences using a tool integrated in CPPsite, to assure that these peptides were 
original and distinct to CPPs currently in that database. 
  
3.1.1. In silico analyses of viralCPP sequences 
Computational analyses of viralCPPs (Annex A) were conducted using several online tools. 
PSIPRED (150) was used to predict viralCPP propensity for formation of secondary structures. 
Heliquest (151) was employed in the construction of helical projections and to infer about the 
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amphipathicity of each peptide sequence. Illustrative secondary structure models were computed by 
PEPstr (152) and Monte Carlo simulations were ran on MCpep server (153) for simulation of 
viralCPP helical content percentage in aqueous and lipid membrane environments. 
 
3.2. viralCPP synthesis and reconstitution 
The 14 viralCPPs were commercially obtained from JPT Technologies (Berlin, Germany), 
having been synthesized by Fmoc solid-phase chemistry to a purity of >90%. All lyophilized 
peptides were reconstituted in Milli-Q water (MerkMillipore Integral Water Purification System). 
Aliquots were prepared at a concentration of 500 µM and stored at -20ºC. 
 
3.3. Chemicals 
All ionic salts used in this work, namely NaCl, KCl, KH2PO4, Na2HPO4, NaF and N-2-
Hydroxyethylpiperazine-N′-2-ethanesulfonic Acid (HEPES), as well as ethanol and spectroscopic 
grade chloroform, were obtained from Merk (Darmstadt, Germany). The lipids POPC and POPS, 
where purchased from Avanti Polar Lipids (Alabaster, AL, USA). The potentiometric probe di-8-
ANEPPS was attained from Sigma-Aldrich (St. Louis, MO, USA). Fluorescent dyes Hoechst 33342 
and CellMask Deep Red, GlutaMAX Dulbeco’s Modified Eagle Medium, optiMEM (reduced 
serum media) , Fetal Bovine Serum (FBS), Penicillin-Streptomycin antibiotic solutions, Tryple 
Express (commercial grade trypsin solution), as well as the stock of ssDNA labeled with Alexa 
Fluor 488 and the Live/dead viability/cytotoxicity kit for mammalian cells, were purchased from 
Life Technologies (Carlsbad, CA, USA),  
 
3.4. Delivery of ssDNA into cells by viralCPPs 
3.4.1. Cell culture procedures 
Human Embryonic Kidney cells (HEK 293) were used to conduct FS and FC analyses, 
while Baby Hamster Kidney fibroblasts (BHK 21) were employed for confocal microscopy 
observations. Both cell lines were obtained from ATCC (Manassas, VA, USA). Cells from both 
lines were cultured using the same procedures. Cryo-preserved cell vials stored at -80ºC in liquid 
nitrogen were quickly thawed in a heated bath at 37ºC immediately prior to culture initiation. The 
cells were then transferred to Thermo Scientific (Waltham, MA, USA) Nunc™ EasYFlasks and 
supplied with fresh GlutaMAX Dulbeco’s Modified Eagle Medium enriched in glucose and 
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pyruvate, and supplemented with 10% v/v FBS and 1% v/v Penicillin-Streptomycin antibiotic 
solution (10 000 U/ml). A growth period of 2-3 days was allowed for cell expansion before 
confluence. A maximum of 4 passages was permitted, to ensure cell viability and phenotypic 
consistency. All cell handling was conducted in a laminar flow hood sterile environment according 
to good laboratory practice standards. A humidified incubator with 5% CO2 atmospheric content at 
37ºC was used for cell storage and growth. Cell counting and viability assessments were made in a 
Millipore (Billerica, MA, USA) Scepter 2.0 Automated Cell Counter using 60 µL disposable sensor 
chips. 
 
3.4.2. Incubation of viralCPP:ssDNA conjugates with HEK cells 
Aliquots of each viralCPP were thawed at room temperature and prepared in small 
eppendorf tubes to be tested at final concentrations of 1, 5 and 10  M. A solution of ssDNA 
oligonucleotides (ACGTGCTGAGCCTAC) labeled with Alexa Fluor-488 fluorescent probes 
(ssDNA-A488) was added to each viralCPP aliquot to be assayed at 0.1  M. Each sample was 
mixed by short spin in an eppendorf (Hamburg, Germany) MiniSpin centrifuge prior to cell 
addition, to promote formation of electrostatically bound viralCPP and ssDNA-A488 conjugates 
(viralCPP:ssDNA-A488). 
HEK 293 cells were washed in standard Phosphate Buffer Saline (PBS), pH 7.4, and 
harvested by trypsinization (2 minute treatment with Tryple Express). Fresh culture medium was 
added to inactivate trypsin activity and to collect the cells. Cell pellets were produced by 
centrifugation at 1250 RPMs for 5 minutes in an eppendorf 5810-R centrifuge, washed twice in 
PBS and resuspended with optiMEM.  
Collected cells were added to the previously prepared viralCPP:ssDNA-A488 aliquots at a 
concentration of         cells/mL to a final volume of 500  L. Incubation proceeded for 1 hour 
in a VWR Incubating Orbital Shaker, at 37ºC and under gentle mixing (100 RPMs). Following 
incubation, pellets were obtained from each sample by centrifugation at 2000 RPM, for 5 minutes at 
room temperature in a Thermo Scientific Heraeus Multifuge 1L-R. The supernatant was discarded 
to remove signal from non-internalized peptide:ssDNA-A488, followed by re-suspension of pellets 
in 500  L of PBS. Controls for the experiment were equally prepared. These included a sample of 
cells and cells incubated with ssDNA-A488 but no peptide. The signal of A488 probe retained per 




3.4.3. Fluorescence spectroscopy  
An Edinburgh Instruments (Livingston, UK) FS920 Fluorescence Spectrometer, equipped 
with 2 double monochromators and a 750 W xenon lamp, was employed for obtaining high-
sensitivity fluorescence intensity spectra from each sample prepared as previously described in 
section 3.4.2. Briefly; 100  L from each of these solutions were diluted 4:1 with PBS. Hellma 
Analytics (Müllheim, Germany) 5x5 mm quartz cuvettes were used to collect the emission spectrum 
of A488 (Figure 2.2 and Annex B1) retained in the samples. Emission scan readings were 
performed at wavelengths ranging from 500 to 650 nm in 1 nm steps with a dwell time of 0.2 
seconds. Three acquisitions were conducted per sample. The excitation wavelength was fixed at 488 
nm and both excitation and emission slits were set at 10 nm. Background was subtracted from every 
emission spectrum. The integral of every spectrum was calculated to quantify total fluorescence 
intensity. The results were plotted as bars displaying the mean value of five replicates and the 
standard error of the mean (SEM).  
 
3.4.4. Microplate fluorescence reading and flow cytometry  
In addition to FS, FC and PR measurements were conducted with the samples descried on 
section 3.4.2. Two volumes (technical replicates), of 200  L each, were distributed per sample into 
the wells of a fluorescence ready V-bottom Eppendorf Polypropylene 96-Well Microplate.  
Fluorescence measurements were recorded by a Tecan (Maenedorf, Switzerland) Infinite 
F500 multimode Microplate Reader in fluorescence top reading mode. Excitation wavelength was 
defined with a 485 nm filter (20 nm bandwidth), while emission wavelength was set with a 535 nm 
filter with 25 nm bandwidth.  
Immediately after PR data collection, the same 96-well plate was measured by FC analyses. 
Fixed volumes of 180 µL per sample were injected into a BD (San Jose, CA, USA) LSRFortessa 
cell analyzer equipped with a high throughput screening module and a blue 488 nm laser. The FL 
530/30 BP channel was used to acquire A488 fluorescence intensity signal as well as FSC and SSC 
signals for each event recorded.  
Background subtraction was performed before plotting of PR and FC data. PR and FC 
A488 fluorescence intensity data were plotted as bars displaying the mean value of five replicates 
and SEM (Annex B.2.3). To quantify the percentage of cells loaded with CPP:ssDNA-A488 in FC 
measurements, positive events were gated using FlowJo v8.7 software, and the ratio of positive 
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events to total number of counts was calculated and plotted as bars displaying the mean value of 
five replicates and SEM. 
 
3.4.5. Effect of trypsin on viralCPP:ssDNA-A488 delivery  
To evaluate the amount of signal obtained from viralCPP:ssDNA-A488 adsorbed at the 
outer leaflet of cell membranes (i.e. retained in samples but not internalized by cells), each sample 
prepared and incubated as previously described in section 3.4.2 was treated with Tryple Express. 
However, cells were resuspended in PBS instead of optiMEM to avoid inhibition of protease 
activity by the culture media. After the initial incubation with viralCPPs at 5 µM and ssDNA-A488 
at 0.1 µM, 5  L of Tryple Express were added to each sample. Tryple is a commercial grade trypsin 
solution, and its formulation has not been disclosed by the manufacturer, therefore 5  L were used 
as the maximum volume that did not compromise cell viability. Incubation with Tryple proceeded 
for 1 minute, at 37ºC, in the same orbital shaker incubator as before. After washing, the samples 
were analyzed by FS, as described in section 3.4.3.  
 
3.4.6. Confocal laser scanning microscopy of CPP:ssDNA-A488 cell internalization 
 For confocal microscopy (CM) observations of viralCPP:ssDNA-A488 in vitro delivery, 
BHK 21 cells were seeded at       cells/mL in iBidi µ-Slides VI plates and grown overnight. 
Staining solutions were prepared, namely Hoechst 33342 at 5 10-2 mg/mL and Cell Mask Deep 
Red at 1.5 10-3 mg/mL. Each well was then gently washed in PBS, and the cells were stained with 
100  L of Hoechst or with a combination of Hoechst and CellMask Deep Red. After 30 minutes of 
incubation, the cells were again washed in buffer and 100  L of a solution of peptide (50 µM) and 
ssDNA-A488 (2  ) were added to each well, followed by 1 hour of incubation. After replacing the 
supernatant with fresh PBS, the samples were observed through an inverted confocal point-scanning 
Zeiss (Jena, Germany) LSM 510 META microscope equipped with Diode 405-30, Argon2, DPSS 
561-10, HeNe 594 and HeNe 633 lasers and a temperature control incubator (37°C) with CO2 
supply. Images were collected with a Plan-Aprochromat 63x objective from Zeiss. The collected 
images were analyzed using ImageJ 1.47v software (154) to remove background noise and create 
composites from the ssDNA-A488 (green), nuclei (Hoechst-blue) and cell membrane (CellMask 





3.4.7. Live/Dead assay 
Live/Dead viability/cytotoxicity kit for mammalian cells (134) is a two colour assay which 
can be used with FC to determine the viability of cell populations. The kit contains two 
fluorophores to stain cells, calcein-AM and ethidium homodimer-1. Calcein fluorescence is 
activated by intracellular esterase activity which is ubiquitous in live mammalian cells. Therefore, 
calcein is employed to discriminate live cells through green fluorescence staining. On the other 
hand, ethidium homodimer-1 is cell-impermeable and labels dead cells with red fluorescence by 
binding to nuclei acids upon loss of plasma membrane integrity. The Live/Dead 
viability/cytotoxicity kit for mammalian cells was used to evaluate the cytotoxicity of viralCPPs on 
HEK 293 cells. Supplier’s indications (134) were followed to prepare staining samples of calcein-
AM and ethidium homodimer-1 for FC analysis. Sample solutions were prepared as described in 
section 3.4.2 at viralCPP concentrations of 5µM and 10 µM. Controls consisted of live cells, and of 
dead cells exposed to 70% isopropanol. Fluorescence measurements were conducted in the same 
cytometer as in previous cases, using a wavelength of 488 nm for excitation and measuring green 
fluorescence emission for calcein (530/30 bandpass) and red fluorescence emission for ethidium 
homodimer-1 (610/20 bandpass). Live and dead populations were plotted and gated as references 
using FlowJo v8.7 (Annex B.2.3) so that percentage of viability could be calculated.  
 
3.5. Biophysical assays 
3.5.1. Preparation of lipid vesicles  
Lipid vesicles were prepared according to standard procedures described elsewhere (148). 
Briefly, the desired amounts of each lipid were individually weighted, dissolved in chloroform and 
mixed in a round bottom flask. The organic solvent was then evaporated via a flux of nitrogen gas 
and stored overnight under vacuum. The lipid film was rehydrated in buffer (HEPES 10mM, NaF 
40mM, pH 7.4) and subjected to 8-10 heating/thawing cycles to promote formation of large 
multilamellar vesicles. LUVs with the desired diameter were obtained using an Avestin LiposoFast-
Basic extruder with a 100 nm sized pore Whatman (Maidstone, UK) Nuclepore membrane filter. 
For SUV preparation the rehydrated films were submitted to power sonication in a 






3.5.2. Di-8-ANEPPS membrane dipole potential sensing assay 
For membrane dipole potential sensing procedures the fluorescent probe di-8-ANEPPS was 
directly added to lipid/chloroform solutions during LUV preparation. In this case, solutions of 
200µM of POPC and POPC/POPS (4:1) were obtained stained with 0.5% (n/n) of di-8-ANEPPS. 
ViralCPPs were initially tested at 10 µM in each lipid system. To assay peptide induced alterations 
in membrane dipole potential, excitation spectra of di-8-ANEPPS were collected before and after 
viralCPP addition to the model membranes, using an Edinburgh Instruments FS920 Fluorescence 
Spectrometer. These spectra (Annex B.4.1) were recorded between 350 nm and 550 nm, in 1 nm 
step single runs of 3s dwell time. Emission wavelength was set at 606 nm with a 3 nm and 8 nm 
slits for excitation and emission respectively. Each spectrum was corrected for background and 
normalized by its underlying area. Sinusoidal differential spectra were obtained (Figure 2.4 and 
Annex B.4.3) by subtracting the normalized spectra collected before and after viralCPP addition. In 
viralCPPs displaying an affinity for model membranes, incremental concentrations were tested to 
perform dual wavelength ratiometric measurements (137). In these cases, excitation spectra were 
collected at viralCPP concentrations of 1, 5 and 10 µM (Annex B.4.2) and differential spectra were 
produced as before (Annex B.4.4). R was calculated for each of these cases as the ratio of 
fluorescence intensities (from excitation spectra) at wavelengths where peaks are observed in the 
differential spectra. Ratio values were normalized for the initial value in undisturbed di-8-ANEPPS 
LUV spectrum (R0). R/R0 was then plotted as mean values of three replicates.  
 
3.5.3. Circular dichroism spectroscopy 
The assessment of viralCPP secondary structure was attained through CD using 
POPC/POPS (4:1) vesicles. CD spectra were acquired with a JASCO (Easton, MD, USA) 
spectropolarimeter model J-815, at 25°C in the 200–260 nm range, using Hellma Analytics 0.1 cm 
quartz cells. ViralCPPs were first assayed at 100 µM in HEPES buffer, in the absence or presence 
of LUVS at incremental concentrations of 0, 0.5, 1, 2, 4 and 6 mM. Each final spectrum 
corresponded to the average of 10 runs, which were subsequently corrected for buffer or LUV 
baselines. Peptides were also assayed under the same conditions using SUVs at concentrations of 0, 
0.5 and 1 mM. All spectra were plotted as a function of mean residue ellipticity, and submitted to 





3.5.4. Dynamic light scattering  
DLS experiments were carried out to assay the hydrodynamic diameter of viralCPPs and 
viralCPP:ssDNA-A488 complexes. These measurements were conducted on a Malvern (Malvern, 
UK) Zetasizer Nano ZS  with backscattering detection at 173°, equipped with a He-Ne laser (632.8 
nm) at 25°C , following 10 min of equilibration, using Hellma Quartz cuvettes with a 3 mm light 
path and center 9.65 mm. Each replicate consisted of 15 measurements, and 2 replicates per sample 
were conducted and averaged. ViralCPP (100 M) and viralCPP(100  M):ssDNA(20  M) solutions 
were then prepared in HEPEs and assayed. To assure complete removal of any foreign particle 
contaminants, every solvent was passed through a 0.45 µm syringe filters from VWR International. 
DLS size/number distribution tables were extracted from the Malvern Zetasizer software v7.02. 
Mean hydrodynamic diameter values were averaged from the results of 2 replicates and plotted as 























4. Results and discussion  
The foundation of this project was provided by several factors. The first was the rational 
that structural viral proteins exhibit a natural affinity for biological membranes. Another issue was 
that CPPs from viral origin have already been described. However, despite these two facts, viruses 
remain an underexplored source of MAPs. Also critical was the identification of two regions in 
DENV C protein which were isolated as potent CPPs, namely pepR and pepM (118, 156). These 
findings led to the hypothesis that structural proteins from viruses are a rich and currently 
underexplored source of CPPs. Under this hypothesis, the work herein described had several 
objectives. The first objective was the identification of novel CPP sequences, termed viralCPPs, 
from putative regions in structural proteins belonging to a wide and diverse sample of viruses. A 
following goal was that of experimentally validating a set of viralCPPs in vitro as potential vectors 
for gene therapy. The last objective was to conduct preliminary biophysical studies to characterize 
this set of viralCPPs in order to understand their efficiency in the delivery of molecular cargo. 
To fulfil these objectives the work was divided into three stages. The first stage concerned the 
prediction of viralCPP sequences with the aid of computational tools. Therefore structural viral 
proteins were identified, and their amino acid sequences were collected, through the ViralZone 
directory. These were, in turn, submitted to CellPPD, an online server for CPP prediction and for 
the identification of probable CPP regions in proteins. 2400 viralCPP sequences were obtained from 
this procedure, each a possible CPP lead. A manageable set of 14 viralCPPs was selected from this 
pool, and synthesized, to be experimentally tested. Thus, in the second stage of the work viralCPPs 
were conjugated with ssDNA-A488 oligonucleotides and were assayed as DDSs for gene therapy. 
HEK 293 cells were incubated with viralCPP:ssDNA-488 and uptake efficiency was evaluated by 
the fluorescence signal of the A-488 probe. This signal was measured by FS and FC. During this 
stage other assays were also conducted. Trypsin was used to assess the adsorption of probe to cell 
membranes; confocal microscopy allowed the visual confirmation of viralCPP-mediated delivery of 
cargo to BHK 21 cells; and a toxicity study was conducted with a Live/Dead cytotoxicity FC kit. In 
the final stage of this work, preliminary biophysical methodologies were employed to assess 
physical-chemical properties of viralCPPs and viralCPP:ssDNA-A488. In this later section 
membrane dipole potential sensing by di-8-ANEPPS was used to study the propensity of each 
viralCPP towards model membranes. CD was employed to determine the formation of secondary 
structures by viralCPPs in the presence of lipid membranes. Finally the formation of CPP/ssDNA 
conjugates was relayed by shifts in hydrodynamic diameters evaluated by DLS spectroscopy. 
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The results obtained from each of these procedures as well as their interpretation, are 
described in this chapter. 
 
4.1. ViralCPPs: identifying novel CPP sequences in structural viral proteins  
 The current section presents results from the first stage of the work, namely the 
identification of viralCPP sequences. As previously mentioned, viralCPPs are novel amino acid 
sequences with CPP potential identified in structural viral proteins through computational 
methodologies. Upon a process of selection from 2400 CPP candidates, a final set of 14 viralCPP 
sequences was obtained for experimental work. These sequences are displayed in Table 4.1, along 
with their SVM score, positive net charge value, virus of origin and protein source.  
This set of viralCPPs was chosen based on several criteria. The first criterion was 
promoting biochemical diversity between amino acid sequences. This is evident in the column of 
Table 4.1 displaying the amino acid sequences of each peptide. In general, the 6 viralCPPs on the 
top of the column (viralCPPs 1415-0979) have lower content in basic amino acid residues and are 
more varied in terms of constitution, whereas the remaining sequences (viralCPPs 0417-0769) are 
more uniform and mainly rich in arginines and lysines. However, no two sequences are identical.  
 A second criterion was that of covering a variety of SVM scores. These ranged from a 
modest 0.06 attributed to viralCPP 0956 and viralCPP 0554, to the highest value of 1.63 associated 
with viralCPP 2319. By standard definition of the CellPPD algorithm, positive SVM scores signify 
CPP potential, and higher-scoring SVM hits are more probable CPPs. As the great majority of 
known CPP sequences are rich in basic amino acid residues, this trend was necessarily reproduced 
in the learning sets that instructed the machine learning algorithm of CellPPD (126). Thus, high 
SVM scores are related to abundance in arginine and lysine content. In fact, presenting a poly-
arginine sequence to CellPPD produces the highest SVM score of 2.6, while the Tat peptide is 
predicted from the amino acid sequence of the TAT protein with an SVM score of 1.3. This bias of 
CellPPD towards basic residues is equally observable in the set of viralCPP sequences. The 8 
viralCPPs on the bottom of Table 4.1 (viralCPPs 0417-0769) are particularly rich in R and K 
residues, exhibit higher positive net charge magnitude, and collectively gather the highest SVM 
values. Conversely, the remaining viralCPPs are more unusual relative to the landscape of currently 
known CPPs by having a lower percentage of basic residues, and therefore present much lower 
SVM scores. This however, justifies their relevancy as study subjects, and also allows that they be 
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Another criterion in the selection of the sequences present in Table 4.1 was that of 
including examples from different CPP families (e.g. amphipathic, cationic, proline-rich). To help 
categorize the viralCPPs, in silico analyses were performed to each amino acid sequence using the 
tools described in section 3.1.1. The results from these procedures can be viewed in Figure 4.1 and 





Figure 4.1 – Example of viralCPP in silico analysis – The amino acid sequence of viralCPP 1415 is 
highlighted in blue for identification of basic residues. On the left, a helical projection is illustrated along with 
the mean amphipatic moment vector. To the right, a tridimensional simulated structure is depicted above a 
prediction of secondary structure. Helical content predicted using Monte Carlo simulations of the peptide in 
aqueous (blue curve) and 20% anionic membrane environment (brown curve) are shown below.  
 
Among these results, the helical projections of viralCPPs (Annex A) produced with the 
Heliquest(151) web tool were used to classify each peptide according to the criteria proposed by 
Milletti (7) and described in section 1.2.3. ViralCPPs 1415, 1203, 0979 and 1754 can be held as 
either cationic or amphipathic proline-rich, because they fulfil the minimum density of charge 
required to be inscribed into the first category (+ 0.2 per residue), but also display considerable 
content in proline residues. Similarly, viralCPP 0956 can be classified as a proline-rich peptide, 
although it is also possible that it be viewed as hydrophobic, due to a very low amount of positive 
charges and the high content in hydrophobic amino acid residues. On the other hand, viralCPPs 
1396 and 0554 can be grouped in the secondary amphipathic category due to the opposing 
distribution of basic and hydrophobic residues in their helical projections. All remaining peptides 
can be ascribed to the cationic family, due to very high content in basic amino acids. However, in 
this subset, viralCPP 0417 can also be considered proline-rich, and there is evidence to support 
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classification of viralCPPs 0275, 2319 and 0769 as secondary amphipatic α-helical peptides. 
Although ambiguous, this categorization effort confirms that representatives of different CPP 
families were indeed present in the viralCPP set. Removing these ambiguities would imply that 
further data concerning viralCPP structure and activity be collected. This biophysical data would be 
used to infer how the biochemical properties of each viralCPP are related to its activity. For 
instance, the structure of every peptide could be determined in aqueous and membrane 
environments through techniques such as CD or nuclear magnetic resonance (42). This would be 
important because secondary conformations are related to amphipathicity, and therefore to CPP 
activity. Furthermore, studying the effect of amino acid substitutions on residues which are 
suspected to play a key role in viralCPP membrane interaction or uptake could also clarify this issue 
(157).  
Another attribute worth stating in the set of viralCPPs is the variety in viral origins. Some 
of these peptides were identified in intensely studied animal (including human) viruses, while the 
set also included viruses from poorly characterized taxa. Three plant viruses also served as origin 
for viralCPPs 1415, 1779 and 0275, namely the indian citrus ringspot virus, the barley yellow dwarf 
virus and the cauliflower mosaic virus. No unifying trend could be distinguished in the overall 
morphology of these viruses. The set contained enveloped and non-enveloped virions, some of 
simple morphology (simple capsid surrounding an oligonucleotide), of distinct RNA and DNA 
genomes and uptake mechanisms. Finally, it can be stated that the majority of these viralCPPs were 
withdrawn from sequences of Capsid proteins, while Envelope proteins were a minority, and no 
examples from Membrane proteins were included.  
 
4.2. Validation of viralCPPs as DDSs for gene therapy 
4.2.1. Delivery of viralCPP:ssDNA-A488 into HEK cells evaluated through FS and FC 
 The second stage of this work had the objective of validating the set of viralCPPs in vitro to 
confirm their activity as CPPs. A protocol was devised for this end, consisting on assaying 
viralCPP-mediated delivery of ssDNA oligonucleotides labeled with a fluorescent probe (A-488) 
though FS and FC. The first step of this protocol was to conjugate each viralCPP (at 1, 5, and 10 
 M) with the oligonucleotide probes (at 0.1 M) via formation of electrostatically bound complexes. 
These conditions allowed that a range of viralCPP:ssDNA-A488 molar ratios - 10:1, 50:1 and 100:1 
– be tested. Each sample of viralCPP:ssDNA-A488 was then incubated with HEK 293 cells. FS was 
used to collect A-488 emission spectra and relay the efficiency of probe delivery to each sample 
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through the quantification of probe fluorescence intensities. On the other hand, FC was used to 
quantify the percentage of positive delivery events in the total population of cells per sample. 
Supplementary fluorescence measurements were also conducted with FC and a PR and are provided 
in Annex B2.    
PepM was chosen as a positive control for these experiments because it is a CPP derived 
from a structural viral protein (C protein of DENV). Moreover, its intracellular delivery capabilities 
were recently characterized, and the peptide demonstrated excellent cellular uptake into several cell 
lines when conjugated with ssDNA cargo identical to the one used in this protocol (117, 118).  
 Figure 4.2 gathers data from FS (upper panel) and FC (lower panel) with respect to 
viralCPP-mediated delivery of ssDNA oligonucleotides in vitro.  
 
Figure 4.2 – Determination of viralCPP efficiency by FS and FC – Peptide concentrations are depicted in 
grey scale, ssDNA controls in white and cell controls in black. (Upper panel) FS Intensity of A488, n = 5 with 
SEM error bars; (Lower Panel) Percentage of positive cell counts by FC, n = 5 with SEM error bars. 
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Both panels of the figure show that cell auto-fluorescence was negligible. The upper panel 
of Figure 4.2 demonstrates that controls of cells incubated with ssDNA-A488 produced low signal 
intensity, signifying that the probe could not be efficiently retained by cells. In contrast, a mean of 
up to 40% in positive cell counts was observed in FC measurements of ssDNA controls, as 
displayed on the lower panel of Figure 4.2. This value indicates that a residual amount of the 
oligonucleotide probe was retained in the samples even in the absence of viralCPPs. Nonetheless, 
this residual signal did not obscure the determination of a viralCPP efficiency profile. Indeed, both 
panels of Figure 4.2 show that viralCPPs 1415, 0956, 1396, 1203, 0554, 0979, as well as 1721 and 
1754, did not improve ssDNA-A488 delivery into HEK 293 cells. As such, in this particular set of 
conditions, there was no evidence to validate them as CPPs. Conversely, viralCPPs 1779, 0417, 
0275, 2319, 0667 and 0769 greatly augmented the signal of ssDNA probe retained in each sample, 
indicating CPP potential in these peptides. Based on these results the set of 14 viralCPPs could be 
divided into 2 groups. The first group was comprised by the 8 peptides which are not CPPs, 
whereas the second group consisted of the 6 viralCPPs validated as CPPs.  
Data form the upper and lower panels of Figure 4.2 also showed that increasing peptide 
concentrations had a positive effect on delivery efficiency. This was true for every CPP with the 
exception of viralCPP 0417. This peptide experienced diminished FS intensity at 10  M, while 
retaining higher ratio of FC positive cell counts relative to 1  M and 5  M. The opposite was true 
for viralCPP 0769 at 5  M, the concentration at which fluorescence intensity was most potentiated, 
but at the cost of a 20% reduction in positive cell counts. Otherwise, every viralCPP produced 
nearly identical efficiency at 5  M and 10  M. Therefore, using viralCPPs at 5 M would be a better 
compromise in terms of potency/dosage relationship. 
It can be seen on the upper panel of Figure 4.2 that pep M’s FS intensity was 2-3 times that 
of the negative sample. However, this effect was much smaller than that of viralCPPs surpassing 
10-fold the control’s fluorescence intensity. Moreover, pepM has been described as highly efficient 
in oligonucleotide delivery (118), a finding which was supported by the FC evidence present in 
Figure 4.2’s lower panel. The success rate of pepM ssDNA delivery was nearby 100%, whereas for 
viralCPPs 0417, 1779, 0275, 0667 and 0769 positive cell count was about 20% lower. On the other 
hand, viralCPP 2319 constituted a very similar case to pepM. This peptide exhibited considerable 
increase in fluorescence intensity relative to control samples, yet a much lower increase than that of 
the other five CPPs. Additionally viralCPP 2319 also demonstrated nearly 100% positive cell 
counts for ssDNA-A488 internalization. Taking into account the evidence of both panels in Figure 
4.2, as well as supplementary PR and FC data in Annex B2, it can be reasoned that pepM and 
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viralCPP 2319 were in fact the most efficient CPPs for delivery of ssDNA-A488 into HEK cells. 
Therefore, pepM and viralCPP 2319 efficiency in ssDNA-A488 delivery might have been 
underestimated by FS measurements, possibly due to phenomena resulting in quenching of A488 
fluorescence. 
 
Correlation between viralCPP SVM scores and delivery efficiency 
Figure 4.3 shows the correlation between the SVM score of each viralCPP and the results 
from FS and FC measurements. This data was used to calculate Pearson correlation coefficients, 
displayed in Table 4.2. 
 
 
Figure 4.3 - Correlation between viralCPP SVM scores and efficiency – (Left panel) Scatter plot illustrating 
correlation between CellPPD SVM scores and FS results; (Right panel) Scatter plot illustrating the correlation 
between CellPPD SVM score and FC results. 
 
Table 4.2 - Pearson correlation coefficient of viralCPP SVM scores and efficiency 
  Pearson Correlation Coefficient 
  Fluorescence Intensity  % Positive Cell Counts 
  Uncorrected              Corrected*   
1µM           0.54   0.87  0.79 
5µM           0.62   0.86  0.90 
10µM           0.55   0.79  0.88 
 





For FS data in the left panel of Figure 4.3 and in Table 4.2, Pearson correlation coefficients 
(~ 0.5-0.6) provided minor support of positive correlation. Figure 4.3 indicates that this was due to 
the contribution of the three data points belonging to viralCPP 2319, corresponding to the highest 
SVM scores (red line crossing coordinate 1.63 of the horizontal axis). It was referred in section 
4.2.1 that the efficiency of viralCPP 2319 as a DDS might have been underestimated by FS 
measurements. Therefore a correction was introduced to this data by rejecting viralCPP 2319 from 
the calculation of Pearson’s coefficient. This correction resulted in improved estimates of 
correlation (> 0.75) between viralCPP SVM score and efficiency. As for FC data, very good 
indicators of correlation were obtained (~0.9). This analysis indicates that CellPPD scores may have 
predictive value in terms of CPP efficiency.  
Indeed, viralCPPs with the lowest SVM scores (< 0.1) were eliminated as CPP candidates, 
as previously discussed (Table 4.1and Figure 4.2). Presumably, low positive net charge was the 
underlying factor for the exclusion of these peptides as CPPs. Apart from low net charge, other 
determinants to explain poor viralCPP delivery might include insufficient/excessive hydrophobicity 
(158) or lack of structural flexibility (42). The exception among the group of low scoring viralCPPs 
was viralCPP 1396. This peptide provides a good example of the difficulty in understanding the 
biochemical requisites for a CPP. It has substantial net charge (+ 8) and its helical projection 
(Annex A) suggests that it can acquire considerable degree of amphipathicity, two factors which are 
shared by a great number of CPPs. However, despite these seemingly favourable traits, viralCPP 
1396 displayed low SVM score and poor delivery efficiency. Understanding this fact would require 
extensive assaying of viralCPP 1396, as the biochemical requisites for CPP activity are still not 
fully characterized. In fact, shuffling CPP sequences or substituting a single amino-acid residue can 
often reduce or even abolish CPP activity completely (157). This indicates that single residue 
positions can be as important to CPP activity as net amino acid content. Two other peptides, namely 
viralCPP 1721 and 1754 were also excluded as CPPs, although exhibiting considerably higher SVM 
scores, respectively 0.63 and 0.23. Nonetheless their charge magnitude was identical to that of 
lower scoring viralCPPs, which might once again explain their lack of efficacy.  
All viralCPP sequences with acidic residues were found to have reduced CPP potential 
(viralCPP 1415, 0956, 1203 and 1721), which suggests that these amino acids were disruptive to 
uptake. For instance, viralCPP 1721 has considerable number of positive charges (10 K residues), 
but a lower net charge of + 8 due to two negatively-charged aspartic acids. Therefore, the exclusion 
of viralCPP 1721 as a CPP supports the hypothesis that net charge is a broader and more critical 
CPP parameter than abundance in positive residues. Electrostatic repulsion between these viralCPPs 
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and ssDNA-A488 or cell membranes may have occurred due to the acidic residues, hampering 
viralCPP delivery efficiency. 
On the other hand, viralCPPs displaying high SVM scores were rich in R and K residues. 
These peptides exhibited a density of positive net charge per amino acid ranging between + 0.45 
and + 0.75. Furthermore, some of these amino acid sequences (Table 4.1) are comprised from 
interesting repetitive patterns. For instance, viralCPP 0417 is constituted by repeats of small 
SPRRR motifs. ViralCPP 0275 is made up by stretches of K residues intercalated with hydrophobic 
tyrosine. An analogous case happens with viralCPP 2319, displaying basic Rs punctuated by 
hydrophobic tryptophan residues. The sequence of viralCPP 0769 is also interesting, with 
hydrophobic leucines on its central part and stretches of R residues at the termini. Current CPP 
literature postulates that positive residues might be responsible for primary electrostatic interactions 
with membranes or extracellular matrix components. Additionally hydrophobic residues are thought 
to promote subsequent insertion of CPPs into biological membranes (52). Therefore these basic and 
hydrophobic residues are related to CPP activity. This finding is in agreement with the amino acid 
content in the group of viralCPPs validated as DDSs. Moreover, viralCPP 2319 was more efficient 
in delivery relative to viralCPP 0275. Both these peptides are similar, but viralCPP 2319 is rich in R 
whereas viralCPP 0275 has K residues. This in agreement with reports in the literature stating that, 
of the two basic residues, R increases CPP efficiency relative to K (39). However, viralCPP 2319 
and 0275 are not perfect R/K analogues, and therefore differences in activity could also be 
explained by content and relative position of hydrophobic residues, or to slight differences in net 
charge magnitude (157).   
  
Advantages and drawbacks of the protocol 
The protocol that was developed for testing the delivery of viralCPP:ssDNA-A488 into 
HEK cells has several advantages. It is a fast, practical, and resource efficient way of assessing CPP 
potential from a large set of leads. As it was the objective of this work to assess viralCPPs as 
potential DDSs, ssDNA oligonucleotide cargo was labeled with an A-488 fluorescent probe. By 
labeling cargo molecules, in place of viralCPPs, it was possible to directly probe the efficiency of 
cargo delivery, instead of simply assessing peptide internalization. In this particular case, the use of 
ssDNA-A488 cargo was envisioned as a model to study the transport of nucleotides for gene 
therapy. Furthermore, probing cargo molecules instead of the peptides avoids the introduction of 
extrinsic hydrophobic/steric effects in the amino acid chains. As such, biophysical studies can be 
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conducted on viralCPPs without artifacts due to labeling (159). Moreover, delivery of any other 
biomolecule could, in principle, be tested just as easily with this protocol, provided that it was 
adequately labeled and could electrostatically bind to the CPPs. Finally, by assaying viralCPPs at 
1 M, 5 M, and 10 M, while maintaining ssDNA-A488 at 0.1  M, different peptide concentrations 
and peptide/cargo ratios were simultaneously tested. This was important because both parameters 
must be tested and optimized to potentiate CPP activity.  
However the protocol also has some drawbacks. It can only provide an indirect assessment 
of CPP potential through measurements of A-488 fluorescence, and thus cannot distinguish 
membrane adsorption of viralCPP:ssDNA-488 from intracellular uptake. Furthermore, successful 
therapeutic delivery often necessitates endosomal escape of the DDSs which cannot be resolved 
through this methodology. However, the protocol could be easily adapted to overcome these 
limitations. For instance, viralCPPs could be used to transfect cells with a reporter plasmid or with 
an antisense oligonucleotide for gene knockdown. These strategies could ascertain if the CPPs can 
promote endosomal escape and functional delivery by exerting phenotypic changes in the cell lines. 
Furthermore, to remove the signal from cargo absorbed at the outer leaflet of cytoplasmic 
membranes, a simple modification was introduced to the protocol, as described in section 4.2.2.  
Given these considerations, the current protocol should be regarded as a reliable method for 
preliminary assessment of CPP potential, i.e. to rapidly exclude poor CPP leads. After this 
assessment, further characterization is required to fully confirm viralCPPs as established DDSs. In 
this regard, CM observations of viralCPP:ssDNA-A488 delivery into live cells were performed, as 
described on section 4.2.3.  
 
4.2.2. Effect of trypsin on viralCPP mediated ssDNA-A488 delivery 
The protocol described in section 4.2.1 has the limitation of accounting for signal from 
probe retained in the cytoplasmic membrane of cells. To resolve this issue, an additional step was 
added to its execution. This modification consisted in treating the cells incubated with 
viralCPP:ssDNA-A488 with trypsin. Trypsin is a serine protease which cleaves peptides at the 
carboxyl terminus of K and R residues. As such, it was used to hydrolyze viralCPPs which might 
have been retained in solution or stuck to the outer leaflet of plasma membranes. This treatment 
removes false positive signals and allows a better estimation of ssDNA-A488 uptake. Thus, 5    of 
TrypLE Express (commercial trypsin solution) were added to each sample after incubation, and 
activated at 37ºC for 1 minute. Afterwards, cells were washed and the protocol was resumed as 
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described in section 4.2.1. TrypLE is a commercial grade trypsin solution and its formulation has 
not been divulged by the manufacturer. As such, the volume of enzyme solution was chosen after 
preliminary trials to minimize losses in cell number and viability. The resulting concentration was 
estimated in the 0.2-1  M range using concentration values found in other commercial formulations 
of trypsin. Figure 4.4 depicts the results from this procedure.  
 
Figure 4.4 – Effect of protease treatment on viralCPP efficiency – Peptide concentration was kept at 5 µM. 
White bars represent untreated samples (n=5), black bars represent samples treated with 5µl of TrypLE 
Express (n=3). Error bars are represented as SEM.  
 
From the decrease in fluorescence intensity after addition of trypsin to each sample, it is 
immediately clear that the protease had a pronounced effect on the amount of probe retained by 
cells. In peptides belonging to the group of non-CPPs (viralCPPs 1415-0979, 1721 and 1754) as 
well as in the oligonucleotide control, the estimate of uptake had about 2-fold decrease. It is 
possible that this effect was related to fragilization of cells by protease activity, perhaps resulting in 
leakage of intracellular content or in a greater amount of pellet loss by washing. However, in the 
remaining viralCPPs, reduction in fluorescence intensity, and hence in delivery, was much higher. 
These findings suggest that a considerable fraction of ssDNA-A488 had been retained in each 
sample due to membrane binding of viralCPP:ssDNA-A488, and not actually to viralCPP promoted 
uptake of oligonucleotide cargo. The percentual decrease in fluorescence was particularly large for 
viralCPPs 0417 and 1779. Conversely, viralCPP 2319 had the smallest percentage of decrease in A-
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488 signal.  Electrostatic attraction between negative moieties in lipid headgroups, or proteoglycans 
in the extracellular matrix, and positively charged amino acid residues, has been implicated in CPP 
activity. ViralCPPs which experienced higher decrease in fluorescence signal were rich in Rs and 
Ks. In these samples, it is possible that excessive affinity towards membranes had been detrimental 
to delivery. Thus, a number of viralCPP:ssDNA-A488 may have not been internalized, instead 
remaining attached to the outer leaflet of the cell surface or inserted in the bilayer. This hypothesis 
would explain the decrease in fluorescence after enzymatic treatment. ViralCPPs would absorb to 
membranes and serve as “anchors” for ssDNA-A488 at the surface of cells. These oligonucleotides 
would therefore be released upon cleavage of the peptides exposed to the extracellular medium by 
trypsin.  
In future trials this experiment may be repeated substituting trypsin with a DNAse solution. 
This would have the advantage of removing non-internalized probe while minimizing disruptions to 
cell viability and morphology relative to trypsin.  
 
4.2.3. Live cell imaging of viralCPP:ssDNA-A488 internalization by CM 
Microscopy observations are an important procedure to confirm CPP activity because 
delivery of cargo can be visually confirmed. CM is particularly useful as images are collected from 
selected focal planes and therefore distinct cell layers can be imaged to assay peptide 
internalization. Primary CM observations had been conducted with HEK 293 cells (the cell line 
used in previous experiments), but image quality was hindered by the characteristic over-
confluency and chaotic growth of this cell line. Therefore BHK 21 cells were used in substitution to 
improve the assessment of delivery. Although CPP uptake can vary between cell lines in vitro, 
observations with BHK 21 were consistent with results from FS and FC in HEK 293 (Figure 4.2). 
This was expected given that both cell types are originated from mammalian kidney. Hoechst probe 
was used to stain cell nuclei (blue), while ssDNA oligonucleotide molecules were imaged due to 
A488 labelling (green). Membrane staining was attempted with Cellmask Deep Red, to mark 
cellular boundaries and co-localize viralCPPs:ssDNA-A488 and cell membranes. However, this 
probe was found to be too erratic to obtain properly stained samples, perhaps due to membrane 
metabolism, flip-flop and recycling. As very poor contrast was systematically obtained upon 
addition of viralCPPs:ssDNA-A488, examples of samples stained with Cellmask Deep Red are 
presented as supplementary data in Annex B3.  
Figure 3.5 shows results obtained from a control of ssDNA-A488 and five peptides. 
ViralCPP 0554 had been excluded as a CPP and was therefore used a negative control. On the other 
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hand, viralCPPs 0275, 2319, 0667 and 0769 belong to the group of peptides which displayed CPP 
activity (Figure 4.4).  
 
Figure 4.5 – CM of viralCPP-mediated ssDNA Delivery – Composite images of Hoechst staining (Blue 
channel) and ssDNA-A488 (Green Channel), with 50 µM of peptide and 2 µM of ssDNA. a) ssDNA control; 
b) viralCPP 0554; c) viralCPP 0667; d) viralCPP 0275; e) viralCPP 2319; f) viralCPP 0769 
 
The top-left image (panel a) shows a field of observation where ssDNA-A488 signal was 
negligible illustrating that ssDNA-A488 alone could not be retained by cells. Similarly, in panel b 
corresponding to viralCPP 0554, small amounts of green fluorescence were obtained in the 
periphery of a few cells, but no evidence for internalization was detected. On the contrary, the 
remaining four panels (c-f) exhibited an increase in the fluorescence of A-488 and provided 
evidence for successful viralCPP-mediated uptake of probe. In this regard, viralCPP 0667 (panel c) 
was the least efficient CPP, producing a diffuse punctuate pattern. ViralCPP 0275 (panel d) 
produced a similar but brighter pattern. The most efficient CPPs are shown in right-ward panels on 
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Figure 4.5, namely viralCPP 2319 (panel e) and viralCPP 0769 (panel f). ViralCPP 2319 also 
produced a punctuate pattern although the dots were brighter and substantially larger than in other 
panels. This pattern was suggestive of endosomal uptake, and proximity to the nuclei further 
supported that viralCPP:ssDNA-A488 internalization was successful. The last panel, corresponding 
to viralCPP 0769, shows intense green fluorescence on the inside of cells, confirming uptake of 
ssDNA-A488.  In this case the pattern was more uniform throughout the cytosol instead of dot-like. 
Due to this fact, it would be interesting to look into the possibility that viralCPP 0769 may enter 
cells via direct translocation. This could be achieved through the study of internalization kinetics 
using FC (118).  
CM observations were in accordance with findings described in section 4.2.1, and have 
confirmed viralCPPs 2319 and 0769 as CPPs. For viralCPP 0275 and 0667 uptake also seemed to 
have taken place, albeit to lower extent. However, these observations can be optimized for a more 
robust assessment of viralCPP-mediated uptake of cargo. In this regard, membrane staining with a 
reliable probe and observing the cells through brightfield transmitted light fluorescence microscopy 
are future objectives. CM can also be useful in determining the internalization mechanism of each 
viralCPP. This could be achieved by incubating the peptides along with inhibitors and probes for 
different pathways of endocytosis to confirm or exclude their role in uptake.             
 
4.2.4. ViralCPP cytotoxicity determination through the Live/Dead assay  
The cytotoxicity profile of viralCPPs was evaluated with the Live/Dead mammalian cell 
kit. This is a two colour assay which uses calcein-AM to stain live cells through green fluorescence, 
and ethidium homodimer-1 to stain dead cells with red fluorescence. HEK 293 cells were incubated 
with viralCPPs at 5 µM and 10 µM, stained with the Live/Dead kit and analyzed by FC.  
Figure 4.6 provides viralCPP cytotoxicity profiles in terms of cell death (upper panel) and 
alterations to morphology (lower panel). Negative controls consisted of live cells, while exposure to 
70% isopropanol was used as reference for cell death. In general all peptides were well-tolerated by 
HEK 293 cells, with values inferior to 5% regarding cell death and to 10% in damage. PepM and 
viralCPP 2319 were exceptions to this pattern. Both peptides displayed similar profiles in either 
panel, exhibiting considerable toxicity at 10 M. However at half that concentration, cytotoxicity 
was diminished. In fact, pepM’s toxicity dropped to less than 10% in cell death and counts of cells 
with damaged morphology. However, viralCPP 2319 retained a high (20%) propensity for inducing 
cell damage. As previously mentioned, a decrease in viralCPP concentration from 10  M to 5  M 
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did not overly alter potency, but these results show that it does alleviate toxicity. Therefore using 
the peptides at 5  M would signify an improvement in therapeutic index.  
The results in Figure 4.5 suggest that viralCPPs do not exhibit levels of toxicity capable of 
impairing their development as DDSs. However cytotoxicity tests in vitro are a very preliminary 
form of screening. Extensive assaying in vivo would be required to establish a safety profile and 
optimize the systems before any form of clinical translation could be envisioned for these peptides. 
 
 
Figure 4.6 – viralCPP toxicity assessment by FC Life/dead assay – Controls of live and dead cells are 
represented in white and black respectively. (Upper panel) Percentage of cells stained with dead marker 
(ethidium homodimer-1), peptide concentrations are represented in shades of red. (Lower panel) Percentage 






4.3. Biophysical assessment of viralCPPs 
The third stage of this work consisted in evaluating the physical-chemical properties of 
viralCPPs and conjugates of viralCPP and ssDNA. The objective of these tests was to identify 
possible reasons why some viralCPPs acted as DDSs, while others did not. Accordingly, the affinity 
of each viralCPP for model membranes was tested via membrane dipole potential sensing with the 
probe di-8-ANEPPS. Afterwards, formation of secondary structures in aqueous and lipid 
environments was investigated by CD. In the final place, DLS was used to evaluate the capacity of 
each peptide to form stable aggregates with ssDNA cargo. 
 
4.3.1. Membrane affinity assayed by di-8-ANEPPS dipole potential sensing  
Macromolecules interacting with lipid bilayers alter their membrane dipole potential. As 
such, dipole potential sensing can be exploited to assess the affinity of MAPs for lipid membranes 
using voltage-sensitive fluorescent probes such as di-8-ANEPPS (141). For this end, a suspension 
of 200 µM POPC LUVs, as well as of 200 µM POPC/POPS (4:1) LUVs, were both prepared 
containing 0.5 % (n/n) di-8-ANEPPS. These vesicles were used to determine whether each 
viralCPP displayed an affinity towards model membranes at 10 µM, the maximum concentration 
used in previous assays. The plots shown in Figures 4.7, 4.8 as well as B.4.3 and B.4.4 (in Annex 
B.4) are differential spectra of di-8-ANEPPS in which peak amplitude relays the magnitude of 
peptide-membrane interactions. Figure 4.7 depicts differential spectra from peptides representing 
two groups of viralCPPs. The upper panels of this image belong to viralCPP 1415 representing the 
group of peptides without affinity for model membranes. Lower panels of the figure display 
viralCPP 0769 which could extensively interact with lipid vesicles and therefore represents the 
group of peptides with membrane affinity. Differential spectra belonging to the remaining 
viralCPPs are presented in Annex B.4 on Figure B.4.3. 
The upper panels of Figure 4.7 demonstrate that viralCPP 1415 could not interact with 
POPC or POPC/POPS LUVS as its differential spectra did not assume a sinusoidal behavior in 
either case. Conversely, for viralCPP 0769 extensive interactions were reported by the amplitude of 
the sinusoidal curve determined in POPC/POPS LUVS, and to a lower extent in POPC LUVs. From 
the spectra present in Figure B.4.3 it was observed that no viralCPP apart from viralCPP 0769 
displayed an affinity for zwitterionic POPC membranes. Moreover, viralCPPs 1415, 0956, 1396, 
1203, 0979, 0417, 1779, 1721 and 1754 could not interact with POPC/POPS LUVs. Conversely, 
viralCPPs 0554, 0275, 2319, 0667 and 0769 displayed an affinity for the anionic POPC/POPS 
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vesicles. A higher magnitude of interaction between viralCPPs and POPC/POPS model membranes 
was expected relative to POPC LUVS. This is due to the fact that net negative charge (conferred by 
POPS) is thought to aid in MAP activity by potentiating electrostatic attraction to the cationic 
residues of the peptides.  
 
Figure 4.7 – Di-8-ANEPPS dipole potential sensing of viralCPP-membrane interactions – Concentration of 
potentiometric probe was kept at 0.5 % (n/n), and viralCPPs were tested at 10 µM (Left panels) Differential 
spectra of interactions reported by di-8-ANEPPS in 200 µM POPC LUVs for viralCPP 1415 (pink) and 
viralCPP 0769 (brown) (Right panels) Differential spectra of interactions reported by di-8-ANEPPS in 200 
µM POPC:POPS (4:1) LUVs for viralCPP 1415 (blue) and 0769 (green). 
 
Because viralCPPs 0554, 0275, 2319, 0667 and 0769 were shown to have an affinity for 
model membranes, these were assayed at incremental concentrations (1, 5 and 10 µM), and assessed 
through dual wavelength ratiometric measurements (137). The left panel on Figure 4.8 shows an 
example of the differential spectra obtained for the three concentrations of viralCPP 0769. Plots 
belonging to the remaining peptides can be consulted in Figure B.4.4. ViralCPP 0275 was excluded 
from this assay because no evidence for interaction was found at concentrations lower than 10 µM. 
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To quantify the magnitude of interaction, the ratiometric approach consists in calculating R, the 
ratio of fluorescence intensities at wavelengths where the crests of the sinusoidal curves occur (e.g. 
RviralCPP 0769 = I385/I500). R was normalized by R0, the ratio of the intensities for the spectrum of 
di-8-ANEPPS in undisturbed LUVs (absence of viralCPPs). These results are illustrated in Figure 
4.8’s right panel.  
 
 
Figure 4.8 – viralCPP dual wavelength ratiometric measurements – (Left panel) Illustration of the shift in 
amplitude of viralCPP 0769 differential spectra due to increase in concentration. (Right panel) Relative 
magnitude of viralCPP-POPC/POPS LUV interactions quantified via normalized ratios of fluorescence 
intensity, mean values from three replicates. 
 
According to these results, viralCPP 0769 induced the highest membrane perturbation of 
the viralCPP set (higher decrease in R/R0) followed by viralCPP 2319, viralCPP 0667 and viralCPP 
0554. All of these peptides caused a shift of the excitation spectra of di-8-ANEPPS towards higher 
wavelengths (Figure B.4.2), i.e. a red-shift. This is confirmed by their sinusoidal differential curves 
(Figure B.4.4), which had negative peaks at lower wavelengths, and positive peaks at higher values 
(the symmetrical happens for blue-shifts, resulting in increments of R with increasing membrane 
perturbation). Red-shifts therefore relay that these viralCPPs decrease membrane dipole potential as 
a result of their interactions with POPC/POPS LUVs. The highest magnitude of POPC/POPS LUV 
membrane dipole potential reduction was caused by viralCPP 0769. It is interesting to note that in 
CM images (Figure 4.5, panel f) viralCPP 0769-mediated uptake displayed a spread of ssDNA-
A488 signal throughout the cytoplasm. This may be explained if the affinity of the peptide for 
membranes is indicative of direct translocation or of the capacity for endosomal disruption. 
However, such a hypothesis requires appropriate validation with biophysical (e.g. evaluate the 
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extent of partition into membranes) and cellular (e.g. FC uptake kinetics) approaches in future 
studies.  
The sequence of viralCPP 0769 is enriched in hydrophobic leucines, with stretches of R 
residues at both termini. This configuration might confer amphipathic properties to the peptide 
which are translated into an affinity for membranes and consequent CPP activity. On the other 
hand, viralCPPs 2319 and 0667 are both highly cationic peptides and thus expected to 
electrostatically bind to anionic POPC/POPS LUVs. ViralCPP 2319 has three tryptophans and an 
isoleucine residue, which are hydrophobic moieties that should aid in membrane insertion, but 
viralCPP 0667 has little content in hydrophobic amino acid residues. However, despite these 
differences, viralCPP 2319 and 0667 exhibited similar degree of interaction. Conversely, viralCPP 
0554 exhibits a much lower magnitude of positive net charge but has higher percentage of 
hydrophobic amino acids in its sequence. Although excluded as a CPP, this peptide was still found 
to have an affinity for POPC/POPS vesicles. This data suggests that peptide-membrane interactions 
and CPP activity depend on a compromise between electrostatic and hydrophobic interactions, and 
that an excess of one of these factors might actually be detrimental to binding and/or insertion (51, 
157). Such findings may explain the behavior of the remaining peptides. In particular, viralCPPs 
0417 and 1779 are highly cationic but did not interfere with the physical environment of membrane 
models, perhaps due to reduced hydrophobicity. Another hypothesis is that they could not be 
correctly assayed via dipole potential sensing due to the promotion of extensive membrane 
aggregation. Furthermore, LUVs are membrane models, and although useful in unveiling the 
biophysical determinants of MAPs, cannot fully replicate interactions with living cell membranes. 
Therefore, the results described in this section do not necessarily contradict previous data 
suggesting that viralCPPs 0417 and 1779 have an affinity for biological membranes (Figures 4.2 
and 4.4). Furthermore the peptides had previously been assessed in conjugation with ssDNA 
molecules, and it is reported in the literature that cargo can alter CPP behavior (59, 117). As such, a 
future set of experiments will assess the affinity of viralCPP and ssDNA conjugates for model 
membranes.  
It should be noted that the concentration of di-8-ANEPPS was kept to a minimum (1 
molecule per 200 lipids) so as not to alter the morphology of the model membranes. Peptide 
concentrations were equally maintained in the range of previous assays (up to 10 µM). Therefore, to 
improve signal/noise ratio and the sensitivity of the test, higher concentrations of probe and/or 
viralCPPs could also be tested. Other assays can be conducted to extract additional information on 
viralCPP-membrane interactions. For instance, partition coefficients of peptide and peptide/cargo 
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complexes can be determined by spectroscopy (137) or zeta-potential (117) measurements, and 
binding affinity could be estimated by surface plasmon resonance (160). 
 
4.3.2. Determination of secondary structures with CD 
Folding into typical secondary structures, such as α-helices and β-sheets, is postulated as an 
important biochemical determinant for MAP activity (157). Indeed, secondary amphipathicity 
acquired by conformational changes seems to play a role in peptide binding and/or disruption of 
lipid bilayers (67). However, as previously mentioned, the impact of this biochemical trait on CPP 
activity remains controversial (40, 42-44). To assess the formation of secondary structures through 
CD, a set of viralCPPs was first selected according to PSIPRED and MCPep helical content 
predictions (Annex A). PSIPRED (150) is a server for analysis of protein sequences, which contains 
algorithms for prediction of peptide secondary structure. MCPep (153) is an online platform for 
Monte Carlo simulation of MAP models in membrane and aqueous environments. ViralCPPs 1721, 
0275, 2319 and 0769 were selected for CD measurements because they were predicted to have the 
highest propensity for acquiring secondary structures. ViralCPP 1721 is 1 of the 8 peptides 
excluded as CPPs, contrary to viralCPPs 0275, 2319 and 0769 which were efficient in the delivery 
of ssDNA into HEK cells (Figure 4.2).  
Initially, POPC/POPS (4:1) LUVs were employed in CD measurements to maintain the 
same conditions as past experiments. Incremental LUV concentrations (up to 6 mM) were added to 
100µM of viralCPP 2319, as indicated in Figure 4.9 and Table 4.3. Spectra were collected between 
200 nm and 240 nm (substantial noise was observed at wavelengths bellow 200 nm due to LUV 
scattering and aggregation) and the data was plotted as mean residue ellipticity. As Figure 4.9 
demonstrates, viralCPP 2319 spectra obtained with POPC/POPS LUVs did not correspond to any of 
the well-defined CD patterns characteristic of secondary structures (Figure 2.5), suggesting that the 
peptides mainly remain as random coils. However a shift towards a signature more suggestive of 
helical features can be observed with an increase in LUV concentration. To quantify the percentage 
of α-helical content, each spectrum was consequently uploaded into the K2D3 server (155). This 
tool uses a neural network algorithm to quantify the percentage of secondary structures in CD 
information uploaded by users by comparison with a reference set of protein CD spectra kept by the 
server. Results obtained from K2D3 are represented in Table 4.3. This data confirms that α-helix 
content was incremented in viralCPP 2319 along with the increase in the concentration of lipid 
vesicles. However, it should be noted that secondary structure prediction with K2D3 does not 
provide a reliable evaluation of secondary structure content in peptides (142). Therefore, Table 4.3 
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should be held qualitatively, to support the progressive modification of secondary structures in 
viralCPP 2319 resulting from the addition of LUVs to the aqueous environment, but not as an 
accurate estimation of helical content. 
 
Figure 4.9 – CD spectra of viralCPP 2319 in POPC/POPS (4:1) LUVs – Secondary structure profile of 
viralCPP 2319 (100 µM) reported via CD in increasing concentrations of POPC/POPS (4:1) LUVs 
 
Table 4.3 – K2D3 prediction of the helical content in CD spectra of viralCPP 2319 in POPC/POPS LUVs 
 
Attempts to improve CD signal were conducted using POPC/POPS (4:1) SUVs. SUVs 
minimize light scattering and are often used to obtain CD measurements with MAPs. Figure 4.10 
illustrates CD spectra for viralCPPs 1721, 0275, 2319 and 0769 at 100µM in increasing 
concentrations of SUVs. Table 4.4 contains the results from the analysis of the spectra by K2D3. 
CD measurements in SUVs did improve viralCPP 2319’s spectrum, as Figure 4.10 illustrates, but 
still no well-defined structures could be inferred for any of the peptides. Both viralCPP 1721 and 
0275 exhibited irregular structures in aqueous environment and upon addition of lipid membranes. 
viralCPP 2319 
LUV [POPC] (mM) 0 0.5 1 2 4 6 
%α-helix200-240 nm 90 93 94 94 95 95 
59 
 
Conversely, for viralCPP 2319 and viralCPP 0769 a shift towards an increase in helical content 
could be observed upon SUV addition. 
 
Figure 4.10 - CD spectra of viralCPPs in POPC/POPS (4:1) SUVs - Secondary structure profile of viralCPPs 
1721 (green), 0275 (red), 2319 (grey) and 0769 (blue) (100µM) reported via CD in increasing concentrations 
of POPC/POPS (4:1) SUVs 
 
Table 4.4 – K2D3 prediction of the helical content in CD spectra of viralCPPs in POPC/POPS SUVs 
viralCPP 1721  0275  2319  0769 
SUV [POPC] (mM) 0 0.5  0 0.5  0 0.5 1  0 0.5 1 
%α-helix200-240 nm 68 93  1.3 1.7  18 94 94  94 94 95 
 
While adoption of typical conformations is often cited as determinant for membrane 
activity, cationic CPPs such as Tat and R9 have been reported to remain unstructured, even in the 
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presence of zwitterionic or anionic membrane models (42). ViralCPPs studied in this section are 
also highly cationic, and as peptides derived from a natural source were not tailored to acquire 
primary or secondary amphipathic properties. Therefore, CD results here described suggest that 
these viralCPPs may be part of a class of naturally disordered CPPs. These results are also partially 
concordant with the simulations that were previously mentioned (Annex A). Indeed, MCpep 
correctly predicted that viralCPP 0769 would have the maximum helical propensity in the set, and 
that minimal shifts in conformation between aqueous medium and anionic membranes would be 
expected for viralCPP 1721 and 0275.  
 
4.3.3. ViralCPP/ssDNA aggregation studied by DLS  
This section marks the conclusion of the preliminary run of biophysical studies on 
viralCPPs. Specifically, the formation of electrostatically bound supramolecular complexes between 
viralCPPs and ssDNA oligonucleotides was studied through DLS. This technique allows the 
determination of the mean hydrodynamic diameters of nanometer scaled particles in solution. 
However, the hydrodynamic diameter may only give a reliable estimate of dimension if the particles 
are spherical. This is not the case for the peptides, nor necessarily for peptide/oligonucleotide 
conjugates. Nonetheless, DLS can relate the apparent size at which dispersed particles are more 
stable. Therefore DLS measurements were used to monitor the mean hydrodynamic diameters of 
peptides in the absence and presence of ssDNA oligonucleotides. Increases in particle size were 
attributed to the formation of peptide/oligonucleotide complexes by non-covalent binding of ssDNA 
with viralCPPs. Concentrations of 100  M and of 20  M were tested for viralCPPs and ssDNA, 
respectively, to optimize measurement conditions. Histograms of the distribution in hydrodynamic 
diameters for each viralCPP are provided in Annex B5. According to this data, viralCPPs often 
demonstrated bi-disperse profiles, i.e. a population of particles with hydrodynamic diameters 
around 1-10 nm and another population with much larger diameters. Therefore, for each sample, the 
two populations were accounted separately by setting a threshold at 10 nm in average 
hydrodynamic diameter. Particles with hydrodynamic diameters at lesser values than 10 nm were 
considered well-dispersed, whereas those of larger diameter were held as micro-aggregates. The 
mean hydrodynamic diameter of each viralCPP population was calculated and is displayed per 
viralCPP, along with the associated percentage in particle number, in Tables 4.5 and 4.6. 
Table 4.5 and Figure B.5.1 contain the results from DLS experiments with viralCPPs 
excluded as DDSs in section 4.2.1. ViralCPPs 1415, 1396 and 1203 showed very residual or 
nonexistent aggregation before addition of ssDNA. On the other hand, viralCPPs 0956, 0554, 0979 
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and 1754 acquired bimodal distributions of hydrodynamic diameter before addition of 
oligonucleotides. The majority of peptides in each of these samples (60-80%) clustered at a scale of 
around 1nm, but some aggregation was also present (20-40%). Conversely, viralCPP 1721 was 
found to be almost completely aggregated in the absence of ssDNA. Upon the addition of 
oligonucleotides, four of these viralCPPs (1415, 1203, 0979 and 1754) retained a considerable 
population of particles with a hydrodynamic diameter of less than 10 nm. This finding supports the 
hypothesis that they did not form stable electrostatic complexes with the ssDNA molecules. In this 
regard, viralCPP 1415 and 1203 were the least efficient in binding to ssDNA because conjugation 
was inexistent. ViralCPPs 0979 and 1754 were similarly poor in terms of electrostatic binding to 
ssDNA oligonucleotides. In these two peptides only about 30% of the total number of particles was 
shown to form complexes. However these complexes had about half the size (~300 nm) of those 
formed in the absence of nucleic material (> 600 nm) indicating that conjugation was partly 
successful. Similarly, viralCPP 1721 was again found to be completely aggregated, but its 
hydrodynamic diameter also decreased by half in the presence of ssDNA.  
 
Table 4.5 – Hydrodynamic diameter of low efficiency viralCPPs 
(µM)  ̅(nm) 
Low Score viralCPP  
1415  0956  1396  1203  0554  0979  1721  1754 








 0-10 1.7  1.4  1.2  1.2  1.2  1.5  3  1 
 93.3%  63.3%  100.0%  100.0%  86.6%  66.6%  3.3%  76.6% 
                
10-
1000 
1043  481  0.0  0.0  604  686  426  823 
 6.7%  36.6%  0.0%  0.0%  13.3%  33.3%  96.6%  23.3% 


















0-10 1.9  2  0.0  2.4  0.0  2.6  0.0  2.5 
 100%  30.0%  0.0%  93.3%  0.0%  76.6%  0.0%  73.3% 
                
10-
1000 
0.0  173  408.0  1163  848.6  349  236.6  323 






















Collectively, these results suggest that for viralCPPs 1415, 1203, 0979, 1754 and 1721, 
poor binding to ssDNA molecules may have been an important justification for their deficiency in 




Although having the lowest magnitude of positive charges (+1) in the set, viralCPP 0956 
was still capable of forming complexes with oligonucleotides. Both this peptide and viralCPP 1415 
have anionic residues in their sequence. In viralCPP 1415 the effect of the aspartic and glutamic 
acid residues might explain the complete absence of electrostatic affinity towards nucleic acids, due 
to repulsion to phosphate groups. Similarly, viralCPPs 1203 and 0554 have the same magnitude of 
positive net charge (+ 6), but the first peptide could not bind to oligonucleotides, possibly due to the 
presence of an aspartic acid in its amino acid sequence. Furthermore the sequence of viralCPP 1721 
also has two negatively-charged amino acid residues, but this peptide was shown to aggregate even 
in the absence of ssDNA, and therefore it was not clear if conjugation occurred.  
Table 4.6 and Figure B.5.2 contain DLS data referent to those viralCPPs which were found 
to acts as CPPs in the delivery of ssDNA in vitro.  
 
Table 4.6 - Hydrodynamic diameter of high efficiency viralCPPs 
(µM)   ̅(nm) 
High Score viralCPP 
0417  1779  0275  2319  0667  0769 









0-10 1.5  1.4  1.6  1.9  1.3  0.0 
 100.0%  90.0%  93.3%  97.8%  96.7%  0.0% 
            
10-1000 0.0  605  1233  14  2010  163.2 
 0.0%  10.0%  6.7%  2.2%  3.3%  100.0% 

















0-10 0.0  0.0  0.0  0.0  0.0  0.0 
 0.0%  0.0%  0.0%  0.0%  0.0%  0.0% 
            
10-1000 991.6  910.7  744.7  104.8  810.0  911.9 
 100.0%  100.0%  100.0%  100.0%  100.0%  100.0% 
 
In general, viralCPPs 0417, 1779, 0275, 2319, 0667 and 0769 demonstrated a different 
behavior than the non-CPPs. For all peptides, except viralCPP 0769, no propensity for spontaneous 
aggregation before ssDNA addition was observed. Furthermore, all 6 viralCPPs were completely 
conjugated upon the addition of ssDNA oligonucleotides, forming monomodal distributions of 
hydrodynamic diameters. These findings are not surprising, given that the peptides have greater 
magnitude of positive net charge (> + 8), and no anionic amino acid residues in their sequences. 
Therefore these viralCPPs are more likely to repel each other and remain well-dispersed in solution, 
while simultaneously demonstrating higher affinity for electrostatic conjugation with negatively-
charged ssDNA molecules. Among this group, two particularly interesting cases were those of 
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viralCPP 2319 and of viralCPP 0769. As Table 4.6 shows, viralCPP 2319 was fully conjugated with 
ssDNA forming a monodisperse population at 100 nm in hydrodynamic diameter. This may have 
happened because it had the highest magnitude of positive net charge (+ 15) and was therefore able 
to form smaller stable conjugates by binding more oligonucleotides per peptide. As such, in less 
cationic viralCPPs electrostatic “nucleation” would proceed until larger, presumably neutral 
structures could be formed. Indeed, in this set of 6 viralCPPs, higher amount of charge was 
correlated (Pearson coefficient of -0.9) with a decrease in hydrodynamic diameter. Conversely, 
viralCPP 0769 was shown to fully aggregate before nucleic acid addition, but a shift in 
hydrodynamic diameter could still be observed from 160 nm to 900 nm, which together with 
previous data is indicative of successful conjugation.  
The electrostatic conjugation between viralCPPs and ssDNA oligonucleotides is a pre-
requisite for their development as DDSs. However, aggregation profiles are also important in the 
optimization of delivery conditions. In an article published by Morris et al. (161)  the authors found 
that the in vitro delivery of cargo mediated by the CPP pep-1 was dependent on the molar ratio 
between cargo and vector. In this study, molar ratio influenced the size of the pep-1/cargo 
complexes and consequently the efficiency of delivery. A molar ratio of 20:1 (pep-1:cargo) was 
found to produce particles with 100 nm in size, as evaluated by DLS and scanning electron 
microscopy. This population of particles sized at around 100 nm was highly efficient in transfecting 
cells. In opposition, different ratios of pep-1 to cargo produced larger particles (> 500 nm) which 
were much less efficient in delivery. These findings by Morris et al. are reminiscent of those 
obtained with viralCPP 2319. Therefore, the fact that viralCPP 2319 was capable of forming 
conjugates centered around 100 nm in hydrodynamic diameter might partly explain why it was an 
efficient viralCPP in the delivery of ssDNA oligonucleotides in vitro.   
 
4.4. From viralCPPs to viralMAPs 
From the set of 14 viralCPPs which have been assayed in vitro, 6 (viralCPPs 1779, 0417, 
0275, 2319, 0667 and 0769) displayed CPP activity. ViralCPP 2319 and 0769 were particularly 
efficient vectors, and would be good leads for continuing development. Therefore a success rate of 
at least 15% could be achieved with the current viralCPP sample. Assuming that this ratio can be 
reproduced in the original pool of 2400 viralCPPs, this means that a minimum of 350 CPP 
sequences are expected to have been found, confirming the hypothesis that structural viral proteins 
are an excellent source of CPPs.  
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 Apart from CPPs, other classes of peptides exist which exert pronounced effects upon lipid 
membranes. These are collectively known as MAPs (114). One of the most extensively studied 
class of MAPs is that of AMPs. These peptides are lytic to pathogens by inducing the disruption of 
their lipid membranes (65). AMPs include peptides capable of antibacterial (119), antiviral (162) 
and even anticancer effects (163). Like CPPs, AMPs are mostly comprised of short amino acid 
sequences. The great majority of these peptides exhibit significant portion of basic amino acid 
residues and the propensity for acquiring amphipathic and/or helical conformations upon membrane 
binding (164). Likewise, exceptions exist in both cases such as peptides of larger dimensions, those 
rich in acidic residues, and others of hydrophobic character (165). Their mechanisms of action are 
also intersected in terms of  biophysical processes, such as the formation of pores or other 
membrane defects (166). Furthermore, understanding of these mechanisms is still very much 
incomplete in both cases (67). In fact, many peptides have demonstrated concurrent antimicrobial 
action and mammalian-cell non-lytic internalization/cargo delivery (167). For instance, potent 
antimicrobial action was discovered in two well-studied CPPs, pVec and transportan 10 (168), as 
well as in tat, penetratin, model amphipathic peptide and pep-1 (169). Furthermore, Bobone et al. 
(170) have recently underlined how subtle differences can dictate a tendency for either 
antimicrobial or cell penetrating activities. Symmetrically, AMPs have also been described to show 
CPP behavior, such as the hLF peptide from human lactoferrin, LL-37 (169, 171).  
Both AMPs and CPPs are highly relevant in the context of biotechnology and 
nanomedicine. AMPs in particular have grown very rapidly as a research field in past few years. 
This is understandable given the urgency in identifying powerful substitutes for conventional 
antibiotics due to the grievous scenario of bacterial resistance (172-174). For instance, AMP 
research abounds in peptides derived from natural proteins found in animals, e.g.  insects, reptiles, 
amphibian, fowls and mammals, to plants and even bacteria (164). However, Figure 4.11shows that 
the total percentage of AMPs derived from viruses is close to inexistent. As with CPPs, the precise 
set of properties that condition the interactions between AMPs and biological membranes is not 
known. However, an increase in the number of AMP databases has allowed the refinement of 
algorithms to detect AMP propensity in amino acid sequences (130, 175). Table 4.7 shows the great 
variety in currently existing AMP databases and prediction servers relative to those dedicated to 
CPPs. Among the tools in Table 4.7, AMPA (176) is a server for the identification of AMP regions 
in amino acid sequences of proteins. It can therefore be viewed as an analogue of CellPPD, 




Figure 4.11 - Sources of AMP Sequences – Each percentage was calculated based on the amount of hits from 
several AMP databases. 
 
Table 4.7 - Currently available databases and prediction tools for AMP and CPP research 





     
 YADAMP 2012 2525 Yet Another AMP database (177) 
 APD2 2004 2329 The Antimicrobial Peptide Database 2 (178) 
 CAMP 2010 5040 Collection of Antimicrobial Peptides (179) 
 LAMP 2012 5547 Linking Antimicrobial Peptides (180) 
 DAMPD 2011 1232 Dragon Antimicrobial Peptides (181) 
CPP      





     
 AMPA 2012  Analyze protein sequence for AMP regions (182) 
 ClassAMP 2012  AMP prediction (183) 
 AntiBP 2 2009  AMP prediction (184) 
 AntiCP 2013  AMP prediction (185) 
 iAMP-2L 2013  AMP prediction  (186) 
CPP      
 CellPPD 2013  Analyze protein sequence for CPP regions (126) 




In this work, structural viral proteins were confirmed as a reliable source of CPPs. Given 
the fact that AMPs are biochemically identical to CPPs and the scenario illustrated by Figure 4.11, 
it would be highly relevant to search for novel AMP sequences in structural proteins from viruses. 
Therefore, AMPA will be used to locate novel AMP sequences, or viralAMPs, in the same pool of 
270 proteins in which viralCPPs were identified. Thus, the success found with viralCPPs has 
motivated the prospect of expanding the opportunities for MAP research in the underexplored but 




























5. Conclusions and Future Prospects 
This work concerned the identification of a type of MAPs, CPPs, from structural proteins of 
distinct virus families. Consequently, its hypothesis was that these components from the global 
proteome of viruses are an abundant and relatively unexplored source of peptide sequences which 
have been tailored by nature to interact with lipid membranes. ViralCPPs tested in this project are 
clear examples that confirmed this statement. Tat, the primordial CPP, is part of a viral protein, and 
a few other CPPs have been found in amino acid sequences from elements of capsids and 
envelopes. As such, the work herein described can be seen as a “back to basics” approach to the 
overall research linked to MAPs.  
In the first stage of this work sequences of CPP propensity were identified in structural viral 
proteins, through the use of the CellPPD server. According to the obtained results, the machine 
learning algorithm implemented in the server could not only correctly identify protein sequences of 
CPP potential, but also predict the expected degree of efficiency of every CPP candidate. This is a 
very useful feature for peptide research, enabling rational grafting and tuning of natural amino acid 
sequences. With this application, a pool of thousands of CPP leads was created, and was 
subsequently refined by clustering and manual selection to produce the final 14 viralCPP set. 
Selection criteria included biochemical diversity and novelty, in detriment of simply searching for 
the highest scoring leads. 
To test these molecules, a screening protocol was developed. Its advantages included low 
biological material requirements, simplicity, and rapid assessment of CPP activity by 
complementary measurements (FS, FC and PR). Probing cargo instead of the peptides themselves is 
advantageous in that no artifacts stem from hydrophobic moieties introduced in the amino acid 
sequences, but it implies that cargoes be labeled with fluorophores prior to testing. Through this 
methodology, it was found that 6 of the 14 peptides had CPP potential to deliver genetic material 
into cells. Protease treatment and CM analyses provided further evidence that two of the peptides, 
namely viralCPP 2319 and viralCPP 0769 were the best and more robust candidates for further 
development as CPPs. For viralCPPs 0417, 1779, 0275 and 0667 further tests have to be conducted 
in order to settle their potential as CPPs. Additionally; it was found that viralCPPs exhibited low 
level of toxicity, as assessed by Life/Dead assay, signifying that they could be further optimized as 
DDSs. 
The last stage of this project consisted in preliminary biophysical characterization of 
viralCPP interactions with lipid membrane models and molecular cargo, namely through di-8-
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ANEPPS membrane dipole potential sensing, CD and DLS spectroscopy. In this regard, it was 
found that poor CPPs were incapable of interacting with membrane models, and in many cases 
could not be conjugated to ssDNA. On the other hand, high-scoring highly-charged cationic 
peptides ubiquitously formed complexes with cargo, and viralCPP 2319 and 0769, in particular, 
were found to induce the highest degree of perturbation in POPC/POPS LUVs. Furthermore, these 
viralCPPs did not acquire a CD profile related to typical secondary structure conformations 
signifying that they are part of the cationic CPP family and remain unstructured in lipids. Thus, 
viralCPPs 2319 and 0769 are the two main candidates for CPP development, whereas viralCPP 
0417, 1779, 0667 and 0275 are contenders which must be subjected to further testing.  
  Future perspectives for the conclusion of this project may include a more in depth study of 
some of these peptides. Further FS, FC and CM assays with additional cell lines/cargoes can be 
conducted, incubating cells under endocytosis blocking conditions (low temperature and endocytic 
inhibitors), determining peptide uptake kinetics, and attempting transfection with a reporter 
plasmid/gene knockdown approach to ascertain endosomal escape and functional cargo delivery. 
Other biophysical trials can also be envisioned, such as membrane fusion assays or the 
determination of partition coefficients through zeta-potential or FS measurements. Following stages 
of this work will also encompass the identification of viralAMPs in the pool of 270 structural viral 
proteins. As with viralCPPs, a set of these antimicrobial agents will be validated in vitro by 
employing standard techniques such as determination of minimum inhibitory concentrations, 
hemolysis and bacterial Live/Dead assays. Finally, bioinformatics approaches might also be 
undertaken to search for evidence of evolutionary biases of viral structural proteins for MAP 
content, in order to establish that these regions serve as biochemical domains for interaction with 
biological bilayers.  
The work described in this document bridged multiple fields, such as drug delivery and 
virology, applying several techniques from diverse areas including bioinformatics, biophysics, and 
molecular biology. Indeed, MAPs are a recent concept with promising applications in intersecting 
areas of biomedical relevance. Thus, expanding the pool of promising leads and the continuing 
efforts to unearth which biochemical features are determinant in this regard are hot-topics in peptide 
research that can contribute with exciting applications to a wide range of medical problems.  
Viruses were one of the primary sources of CPPs, but remain relatively unexplored as a 
natural reservoir of MAPs. Structural viral proteins have been shaped by evolution to counter the 
imposing frontier of cell membranes and are therefore a natural reservoir for MAPs that can now be 
mined through a combination of computational tools and experimental techniques. As such, this 
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work and its future stages will re-establish viruses, complex molecular machines, as frontrunners in 
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Annex A – viralCPP simulations 
Computational analyses were conducted using several online tools. PSIPRED (150) was 
used to predict viralCPP propensity for secondary structure formation (Conf bars represent 
confidence of prediction per residue; Pink cylinders mark helical propensity, Yellow arrows mark 
β-sheet propensity, Black lines mark coiled regions). Heliquest (151) was used to construct helical 
projections of the sequences with a biochemical colour coding of the amino acid residues (Basic – 
Blue; Acidic – Red; Proline – Green; Highly Hydrophobic – Yellow; Hydrophobic– Grey; Histidine 
– Light Blue; Neutral – Purple) and indication of mean amphipathic moment vector. Illustrative 
tertiary structural models were computed by PEPstr (152). Monte Carlo simulations were run on the 
MCpep server (153) for prediction of viralCPP helical content in aqueous (blue line) and 20% 
anionic lipid membrane environments (brown line).      
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Annex B – Supplementary data 




Figure B.1 – A-488 emission spectra collected for a replicate of the viralCPP/ssDNA delivery test. The 



















































B2 – Microplate reader and flow cytometry  
 
 
Figure B.2.1 – Mean of fluorescence measurements obtained with a PR (n = 5, SEM)  
 
 
Figure B.2.2 – Mean of FC fluorescence intensity measurements (n=5, SEM) computed through the 
















































































Figure B.2.3 – (Left panel) FC results from viralCPP mediated uptake of ssDNA-A488. Scatterplot of 
forward (FSC) and side-scattered (SSC) light displaying a gated population of cells in which delivery was 
successful. (Right panel) Live/dead assay of a sample of live cells, mostly stained with calcein, and of dead 
cells stained with ethidium. Apoptotic cells are stained by both dyes. Plots of FSC vs SSC can also be used to 



















B3 – Confocal microscopy 
 
 
Figure B.3 – Examples of erratic Cellmask Deep Red membrane staining in CM images. Staining of 
membranes was successful in the panels related to viralCPP 0275, but was negligible with viralCPP 2319 
samples. In the row further down (viralCPP 0769) only two of the cells in the observation field could be 





B4 – Membrane dipole potential sensing  
 
 
Figure B.4.1 – Excitation spectra of di-8-ANEPPS in LUVs before (black line) and after peptide additions. 
Upon normalization of each measurement, differential curves are obtained by subtracting the black spectrum 













































Figure B.4.2 - Excitation spectra of di-8-ANEPPS in LUVs before (black line) and after viralCPP 0769 
additions at increasing concentration. Intensity values from these spectra are used to compute R and R0 upon 






























Figure B.4.3 - (Upper panels) Differential spectra of interactions reported by di-8-ANEPPS in POPC LUVs, 
viralCPP are split into two sets in shades of red. (Lower panels) Differential spectra of interactions reported 
by di-8-ANEPPS in POPC:POPS (4:1) LUVs, blue shaded set represents viralCPP without membrane 




Figure B.4.4 - Illustration of shifts in amplitude of viralCPP differential spectra due to increases in peptide 
concentration. viralCPP 0956 represented as a negative control. viralCPP 0275 membrane perturbations could 








Figure B.5.1 – Hydrodynamic diameter of poor viralCPP leads before (upper panel) and after ssDNA 




Figure B.5.2 – Hydrodynamic diameter of good viralCPP leads before (upper panel) and after ssDNA 
conjugation (lower pannel) n=2 
 
 
 
 
